WO2010115869A1 - Propofol phosphonyl derivatives, synthesis, and use in long acting formulations - Google Patents
Propofol phosphonyl derivatives, synthesis, and use in long acting formulations Download PDFInfo
- Publication number
- WO2010115869A1 WO2010115869A1 PCT/EP2010/054502 EP2010054502W WO2010115869A1 WO 2010115869 A1 WO2010115869 A1 WO 2010115869A1 EP 2010054502 W EP2010054502 W EP 2010054502W WO 2010115869 A1 WO2010115869 A1 WO 2010115869A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chloride
- propofol
- structural formula
- group
- halogen
- Prior art date
Links
- 229960004134 propofol Drugs 0.000 title claims description 51
- 239000000203 mixture Substances 0.000 title description 37
- 238000009472 formulation Methods 0.000 title description 14
- 230000015572 biosynthetic process Effects 0.000 title description 3
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 27
- 150000002367 halogens Chemical class 0.000 claims abstract description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 17
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 12
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 10
- 150000001768 cations Chemical class 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims description 104
- -1 acyclic diol Chemical class 0.000 claims description 87
- 238000000034 method Methods 0.000 claims description 48
- 239000000543 intermediate Substances 0.000 claims description 40
- 238000004519 manufacturing process Methods 0.000 claims description 35
- 125000005499 phosphonyl group Chemical group 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 229910052698 phosphorus Inorganic materials 0.000 claims description 16
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 15
- 239000011574 phosphorus Substances 0.000 claims description 15
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 12
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 206010002091 Anaesthesia Diseases 0.000 claims description 8
- 229910005948 SO2Cl Inorganic materials 0.000 claims description 8
- 230000037005 anaesthesia Effects 0.000 claims description 8
- 238000012423 maintenance Methods 0.000 claims description 8
- 150000001298 alcohols Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- 125000002015 acyclic group Chemical group 0.000 claims description 5
- 229940125684 antimigraine agent Drugs 0.000 claims description 5
- 239000002282 antimigraine agent Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- MIBQYWIOHFTKHD-UHFFFAOYSA-N adamantane-1-carbonyl chloride Chemical compound C1C(C2)CC3CC2CC1(C(=O)Cl)C3 MIBQYWIOHFTKHD-UHFFFAOYSA-N 0.000 claims description 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 3
- 230000004799 sedative–hypnotic effect Effects 0.000 claims description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 2
- CNDHHGUSRIZDSL-UHFFFAOYSA-N 1-chlorooctane Chemical compound CCCCCCCCCl CNDHHGUSRIZDSL-UHFFFAOYSA-N 0.000 claims description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 claims description 2
- DBTGFWMBFZBBEF-UHFFFAOYSA-N 2,4-dimethylpentane-2,4-diol Chemical compound CC(C)(O)CC(C)(C)O DBTGFWMBFZBBEF-UHFFFAOYSA-N 0.000 claims description 2
- ZWNMRZQYWRLGMM-UHFFFAOYSA-N 2,5-dimethylhexane-2,5-diol Chemical compound CC(C)(O)CCC(C)(C)O ZWNMRZQYWRLGMM-UHFFFAOYSA-N 0.000 claims description 2
- SGEBCUSJUMCJGH-UHFFFAOYSA-N 2-(3-bicyclo[2.2.1]heptanyl)acetyl chloride Chemical compound C1CC2C(CC(=O)Cl)CC1C2 SGEBCUSJUMCJGH-UHFFFAOYSA-N 0.000 claims description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 claims description 2
- VABYVFZVTIDNOA-UHFFFAOYSA-N 2-cyclohexylacetyl chloride Chemical compound ClC(=O)CC1CCCCC1 VABYVFZVTIDNOA-UHFFFAOYSA-N 0.000 claims description 2
- NILLIUYSJFTTRH-UHFFFAOYSA-N 2-cyclopentylacetyl chloride Chemical compound ClC(=O)CC1CCCC1 NILLIUYSJFTTRH-UHFFFAOYSA-N 0.000 claims description 2
- KGMWXVAUXAJKIV-UHFFFAOYSA-N 2-methylcyclohexane-1-carbonyl chloride Chemical compound CC1CCCCC1C(Cl)=O KGMWXVAUXAJKIV-UHFFFAOYSA-N 0.000 claims description 2
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 claims description 2
- SEKYBRONIVJVNW-UHFFFAOYSA-N 3-(1,3-dioxan-2-yl)-2-methylpropanoyl chloride Chemical compound ClC(=O)C(C)CC1OCCCO1 SEKYBRONIVJVNW-UHFFFAOYSA-N 0.000 claims description 2
- AKRRFIAVCHENBI-UHFFFAOYSA-N 3-(1,3-dioxan-2-yl)propanoyl chloride Chemical compound ClC(=O)CCC1OCCCO1 AKRRFIAVCHENBI-UHFFFAOYSA-N 0.000 claims description 2
- UNSAJINGUOTTRA-UHFFFAOYSA-N 3-(3-bromophenyl)prop-2-yn-1-ol Chemical compound OCC#CC1=CC=CC(Br)=C1 UNSAJINGUOTTRA-UHFFFAOYSA-N 0.000 claims description 2
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 claims description 2
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 claims description 2
- QTFYECBIEPDEDY-UHFFFAOYSA-N 3-methylcyclohexane-1-carbonyl chloride Chemical compound CC1CCCC(C(Cl)=O)C1 QTFYECBIEPDEDY-UHFFFAOYSA-N 0.000 claims description 2
- ODYARUXXIJYYNA-UHFFFAOYSA-N 4-methylcyclohexane-1-carbonyl chloride Chemical compound CC1CCC(C(Cl)=O)CC1 ODYARUXXIJYYNA-UHFFFAOYSA-N 0.000 claims description 2
- WJVQJXVMLRGNGA-UHFFFAOYSA-N 5-bromopentan-1-ol Chemical compound OCCCCCBr WJVQJXVMLRGNGA-UHFFFAOYSA-N 0.000 claims description 2
- FCMCSZXRVWDVAW-UHFFFAOYSA-N 6-bromo-1-hexanol Chemical compound OCCCCCCBr FCMCSZXRVWDVAW-UHFFFAOYSA-N 0.000 claims description 2
- MMXRRNUXCHUHOE-UHFFFAOYSA-N 7-bromoheptan-1-ol Chemical compound OCCCCCCCBr MMXRRNUXCHUHOE-UHFFFAOYSA-N 0.000 claims description 2
- GMXIEASXPUEOTG-UHFFFAOYSA-N 8-bromooctan-1-ol Chemical compound OCCCCCCCCBr GMXIEASXPUEOTG-UHFFFAOYSA-N 0.000 claims description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 2
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 claims description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 2
- 239000012346 acetyl chloride Substances 0.000 claims description 2
- WEDIIKBPDQQQJU-UHFFFAOYSA-N butane-1-sulfonyl chloride Chemical compound CCCCS(Cl)(=O)=O WEDIIKBPDQQQJU-UHFFFAOYSA-N 0.000 claims description 2
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 claims description 2
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 claims description 2
- CIYPNZYEUZQIHN-UHFFFAOYSA-N cycloheptanecarbonyl chloride Chemical compound ClC(=O)C1CCCCCC1 CIYPNZYEUZQIHN-UHFFFAOYSA-N 0.000 claims description 2
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 claims description 2
- MJWVCJUSRGLHFO-UHFFFAOYSA-N cyclohexanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CCCCC1 MJWVCJUSRGLHFO-UHFFFAOYSA-N 0.000 claims description 2
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 claims description 2
- HZVKYZHPDGEECE-UHFFFAOYSA-N cyclopentanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CCCC1 HZVKYZHPDGEECE-UHFFFAOYSA-N 0.000 claims description 2
- WCKKWABZCCKDTN-UHFFFAOYSA-N decane-1-sulfonyl chloride Chemical compound CCCCCCCCCCS(Cl)(=O)=O WCKKWABZCCKDTN-UHFFFAOYSA-N 0.000 claims description 2
- IPIVAXLHTVNRBS-UHFFFAOYSA-N decanoyl chloride Chemical compound CCCCCCCCCC(Cl)=O IPIVAXLHTVNRBS-UHFFFAOYSA-N 0.000 claims description 2
- NQGIJDNPUZEBRU-UHFFFAOYSA-N dodecanoyl chloride Chemical compound CCCCCCCCCCCC(Cl)=O NQGIJDNPUZEBRU-UHFFFAOYSA-N 0.000 claims description 2
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 claims description 2
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 claims description 2
- AEHJDQSLTMFLQO-UHFFFAOYSA-N hexane-1-sulfonyl chloride Chemical compound CCCCCCS(Cl)(=O)=O AEHJDQSLTMFLQO-UHFFFAOYSA-N 0.000 claims description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 2
- XMWFMEYDRNJSOO-UHFFFAOYSA-N morpholine-4-carbonyl chloride Chemical compound ClC(=O)N1CCOCC1 XMWFMEYDRNJSOO-UHFFFAOYSA-N 0.000 claims description 2
- KXIBCCFSAMRWIC-UHFFFAOYSA-N morpholine-4-sulfonyl chloride Chemical compound ClS(=O)(=O)N1CCOCC1 KXIBCCFSAMRWIC-UHFFFAOYSA-N 0.000 claims description 2
- NTQYXUJLILNTFH-UHFFFAOYSA-N nonanoyl chloride Chemical compound CCCCCCCCC(Cl)=O NTQYXUJLILNTFH-UHFFFAOYSA-N 0.000 claims description 2
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 claims description 2
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 claims description 2
- WIVNTNLDTMNDNO-UHFFFAOYSA-N octane-1-sulfonyl chloride Chemical compound CCCCCCCCS(Cl)(=O)=O WIVNTNLDTMNDNO-UHFFFAOYSA-N 0.000 claims description 2
- DVCFNCQPOANJGU-UHFFFAOYSA-N oxolane-2-carbonyl chloride Chemical compound ClC(=O)C1CCCO1 DVCFNCQPOANJGU-UHFFFAOYSA-N 0.000 claims description 2
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 claims description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 2
- KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 claims description 2
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 claims description 2
- XACWJIQLDLUFSR-UHFFFAOYSA-N pyrrolidine-1-carbonyl chloride Chemical compound ClC(=O)N1CCCC1 XACWJIQLDLUFSR-UHFFFAOYSA-N 0.000 claims description 2
- JRIQCVWTPGVBBH-UHFFFAOYSA-N pyrrolidine-1-sulfonyl chloride Chemical compound ClS(=O)(=O)N1CCCC1 JRIQCVWTPGVBBH-UHFFFAOYSA-N 0.000 claims description 2
- 229940043375 1,5-pentanediol Drugs 0.000 claims 1
- STPXIOFWKOIYHX-UHFFFAOYSA-N 1-methylcyclohexane-1-carbonyl chloride Chemical compound ClC(=O)C1(C)CCCCC1 STPXIOFWKOIYHX-UHFFFAOYSA-N 0.000 claims 1
- SIJLYRDVTMMSIP-UHFFFAOYSA-N 4-Bromo-1-butanol Chemical compound OCCCCBr SIJLYRDVTMMSIP-UHFFFAOYSA-N 0.000 claims 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 125000000217 alkyl group Chemical group 0.000 description 20
- 239000000651 prodrug Substances 0.000 description 17
- 229940002612 prodrug Drugs 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 239000008063 pharmaceutical solvent Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000002736 nonionic surfactant Substances 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 206010039897 Sedation Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000003474 anti-emetic effect Effects 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000036280 sedation Effects 0.000 description 4
- 238000010956 selective crystallization Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 229940072271 diprivan Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000005809 status epilepticus Diseases 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FDZSOJOJVCBNNI-UHFFFAOYSA-N 1-tert-butylcyclohexan-1-ol Chemical compound CC(C)(C)C1(O)CCCCC1 FDZSOJOJVCBNNI-UHFFFAOYSA-N 0.000 description 2
- ICKWICRCANNIBI-UHFFFAOYSA-N 2,4-di-tert-butylphenol Chemical compound CC(C)(C)C1=CC=C(O)C(C(C)(C)C)=C1 ICKWICRCANNIBI-UHFFFAOYSA-N 0.000 description 2
- HTSABYAWKQAHBT-UHFFFAOYSA-N 3-methylcyclohexanol Chemical compound CC1CCCC(O)C1 HTSABYAWKQAHBT-UHFFFAOYSA-N 0.000 description 2
- MQWCXKGKQLNYQG-UHFFFAOYSA-N 4-methylcyclohexan-1-ol Chemical compound CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 150000001450 anions Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229940093476 ethylene glycol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical group CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 2
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 229930006727 (-)-endo-fenchol Natural products 0.000 description 1
- YTCJPMWRBDVDMB-ZQMQSLPDSA-N (1S,3R,4S,6R,7S,9R,10R,11R,12S,14R,16R,17S,19R,21R,22S,24R,26R,27S,29R,31R,32S,34R,36R,37S,39R,41R,42S,44R,46R,47S,49R,51R,52S,54R,56R,57S,59R,61R,62S,64R,65R,66R,67R,69R,70R,71R,72R,73R,74R,75R,76R,77R,78R,79R,80R,81R,82R,83R,84R,85R,86R,87R,88R,89R,91S)-6,16,21,26,31,36,41,46,51,56,61,67,89-tridecakis(hydroxymethyl)-2,5,8,13,15,18,20,23,25,28,30,33,35,38,40,43,45,48,50,53,55,58,60,63,68,90-hexacosaoxatetradecacyclo[62.2.2.29,12.214,17.219,22.224,27.229,32.234,37.239,42.244,47.249,52.254,57.259,62.13,7]hennonacontane-4,10,11,65,66,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,91-hexacosol Chemical compound OC[C@H]1O[C@H](O)[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@@H]9[C@@H](CO)O[C@H](O[C@@H]%10[C@@H](CO)O[C@H](O[C@@H]%11[C@@H](CO)O[C@H](O[C@@H]%12[C@@H](CO)O[C@H](O[C@@H]%13[C@@H](CO)O[C@H](O[C@@H]%14[C@@H](CO)O[C@H](O[C@H]1[C@@H]2O)[C@H](O)[C@H]%14O)[C@H](O)[C@H]%13O)[C@H](O)[C@H]%12O)[C@H](O)[C@H]%11O)[C@H](O)[C@H]%10O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O YTCJPMWRBDVDMB-ZQMQSLPDSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- 0 **C1C2C3=C(C*4)C4C3C3[C@@]2C3C1 Chemical compound **C1C2C3=C(C*4)C4C3C3[C@@]2C3C1 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- VTBOTOBFGSVRMA-UHFFFAOYSA-N 1-Methylcyclohexanol Chemical compound CC1(O)CCCCC1 VTBOTOBFGSVRMA-UHFFFAOYSA-N 0.000 description 1
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- CAKWRXVKWGUISE-UHFFFAOYSA-N 1-methylcyclopentan-1-ol Chemical compound CC1(O)CCCC1 CAKWRXVKWGUISE-UHFFFAOYSA-N 0.000 description 1
- UKANCZCEGQDKGF-UHFFFAOYSA-N 1-methylpiperidin-3-ol Chemical compound CN1CCCC(O)C1 UKANCZCEGQDKGF-UHFFFAOYSA-N 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- FLVFPAIGVBQGET-UHFFFAOYSA-N 1-methylpyrrolidin-3-ol Chemical compound CN1CCC(O)C1 FLVFPAIGVBQGET-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HMSVXZJWPVIVIV-UHFFFAOYSA-N 2,2-dimethylpentan-3-ol Chemical compound CCC(O)C(C)(C)C HMSVXZJWPVIVIV-UHFFFAOYSA-N 0.000 description 1
- RFZHJHSNHYIRNE-UHFFFAOYSA-N 2,3-dimethylpentan-3-ol Chemical compound CCC(C)(O)C(C)C RFZHJHSNHYIRNE-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JCRNSBKSAQHNIN-UHFFFAOYSA-N 2,4-dibutylnaphthalene-1-sulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(CCCC)=CC(CCCC)=C21 JCRNSBKSAQHNIN-UHFFFAOYSA-N 0.000 description 1
- BAYAKMPRFGNNFW-UHFFFAOYSA-N 2,4-dimethylpentan-3-ol Chemical compound CC(C)C(O)C(C)C BAYAKMPRFGNNFW-UHFFFAOYSA-N 0.000 description 1
- VYONOYYDEFODAJ-UHFFFAOYSA-N 2-(1-Aziridinyl)ethanol Chemical compound OCCN1CC1 VYONOYYDEFODAJ-UHFFFAOYSA-N 0.000 description 1
- FYVMBPXFPFAECB-UHFFFAOYSA-N 2-(1-methylpyrrolidin-2-yl)ethanol Chemical compound CN1CCCC1CCO FYVMBPXFPFAECB-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 1
- JDSQBDGCMUXRBM-UHFFFAOYSA-N 2-[2-(2-butoxypropoxy)propoxy]propan-1-ol Chemical group CCCCOC(C)COC(C)COC(C)CO JDSQBDGCMUXRBM-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- QJQZRLXDLORINA-UHFFFAOYSA-N 2-cyclohexylethanol Chemical compound OCCC1CCCCC1 QJQZRLXDLORINA-UHFFFAOYSA-N 0.000 description 1
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical class CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- NDVWOBYBJYUSMF-UHFFFAOYSA-N 2-methylcyclohexan-1-ol Chemical compound CC1CCCCC1O NDVWOBYBJYUSMF-UHFFFAOYSA-N 0.000 description 1
- BVIJQMCYYASIFP-UHFFFAOYSA-N 2-methylcyclopentan-1-ol Chemical compound CC1CCCC1O BVIJQMCYYASIFP-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- LWHKUVOYICRGGR-UHFFFAOYSA-N 3-bicyclo[2.2.1]heptanylmethanol Chemical compound C1CC2C(CO)CC1C2 LWHKUVOYICRGGR-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- CLYAQFSQLQTVNO-UHFFFAOYSA-N 3-cyclohexylpropan-1-ol Chemical compound OCCCC1CCCCC1 CLYAQFSQLQTVNO-UHFFFAOYSA-N 0.000 description 1
- IBMXMCXCSPGCDQ-UHFFFAOYSA-N 3-cyclopentylpropan-1-ol Chemical compound OCCCC1CCCC1 IBMXMCXCSPGCDQ-UHFFFAOYSA-N 0.000 description 1
- VEALHWXMCIRWGC-UHFFFAOYSA-N 3-methylcyclopentan-1-ol Chemical compound CC1CCC(O)C1 VEALHWXMCIRWGC-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 1
- OIBKGNPMOMMSSI-UHFFFAOYSA-N 4,4-dimethylpentan-2-ol Chemical compound CC(O)CC(C)(C)C OIBKGNPMOMMSSI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N 4-nonylphenol Chemical compound CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- IPNRODMULRDGPT-UHFFFAOYSA-N 5-(hydroxymethyl)-3h-furan-2-one Chemical compound OCC1=CCC(=O)O1 IPNRODMULRDGPT-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- IAIHUHQCLTYTSF-MRTMQBJTSA-N Fenchyl alcohol Chemical compound C1C[C@]2(C)[C@H](O)C(C)(C)[C@H]1C2 IAIHUHQCLTYTSF-MRTMQBJTSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical group 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- VCOJPHPOVDIRJK-LURJTMIESA-N [(2s)-1-methylpyrrolidin-2-yl]methanol Chemical compound CN1CCC[C@H]1CO VCOJPHPOVDIRJK-LURJTMIESA-N 0.000 description 1
- OBAROBUURLBLOI-UHFFFAOYSA-N [2,6-di(propan-2-yl)phenyl] dodecyl hydrogen phosphate Chemical compound CCCCCCCCCCCCOP(O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C OBAROBUURLBLOI-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- VLLNJDMHDJRNFK-UHFFFAOYSA-N adamantan-1-ol Chemical compound C1C(C2)CC3CC2CC1(O)C3 VLLNJDMHDJRNFK-UHFFFAOYSA-N 0.000 description 1
- FOWDOWQYRZXQDP-UHFFFAOYSA-N adamantan-2-ol Chemical compound C1C(C2)CC3CC1C(O)C2C3 FOWDOWQYRZXQDP-UHFFFAOYSA-N 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000002676 chrysenyl group Chemical group C1(=CC=CC=2C3=CC=C4C=CC=CC4=C3C=CC12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- WPOPOPFNZYPKAV-UHFFFAOYSA-N cyclobutylmethanol Chemical compound OCC1CCC1 WPOPOPFNZYPKAV-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- SFVWPXMPRCIVOK-UHFFFAOYSA-N cyclododecanol Chemical compound OC1CCCCCCCCCCC1 SFVWPXMPRCIVOK-UHFFFAOYSA-N 0.000 description 1
- JQYWAZNRRQRPNN-UHFFFAOYSA-N cyclododecylmethanol Chemical compound OCC1CCCCCCCCCCC1 JQYWAZNRRQRPNN-UHFFFAOYSA-N 0.000 description 1
- QCRFMSUKWRQZEM-UHFFFAOYSA-N cycloheptanol Chemical compound OC1CCCCCC1 QCRFMSUKWRQZEM-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- BMCQFFXPECPDPS-UHFFFAOYSA-N cycloheptylmethanol Chemical compound OCC1CCCCCC1 BMCQFFXPECPDPS-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- VSSAZBXXNIABDN-UHFFFAOYSA-N cyclohexylmethanol Chemical compound OCC1CCCCC1 VSSAZBXXNIABDN-UHFFFAOYSA-N 0.000 description 1
- FHADSMKORVFYOS-UHFFFAOYSA-N cyclooctanol Chemical compound OC1CCCCCCC1 FHADSMKORVFYOS-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ISQVBYGGNVVVHB-UHFFFAOYSA-N cyclopentylmethanol Chemical compound OCC1CCCC1 ISQVBYGGNVVVHB-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 1
- XSFJMMWTLXMXTK-UHFFFAOYSA-N cycloundecylmethanol Chemical compound OCC1CCCCCCCCCC1 XSFJMMWTLXMXTK-UHFFFAOYSA-N 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- 239000012969 di-tertiary-butyl peroxide Substances 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- LWYLQNWMSGFCOZ-UHFFFAOYSA-L disodium 2,6-bis(propan-2-yl)phenoxymethyl phosphate Chemical compound [Na+].[Na+].CC(C)C1=CC=CC(C(C)C)=C1OCOP([O-])([O-])=O LWYLQNWMSGFCOZ-UHFFFAOYSA-L 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013266 extended drug release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- IAIHUHQCLTYTSF-UHFFFAOYSA-N fenchyl alcohol Natural products C1CC2(C)C(O)C(C)(C)C1C2 IAIHUHQCLTYTSF-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000003914 fluoranthenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC=C4C1=C23)* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- UCVODTZQZHMTPN-UHFFFAOYSA-N heptanoyl chloride Chemical compound CCCCCCC(Cl)=O UCVODTZQZHMTPN-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000001457 metallic cations Chemical class 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- PCPUMGYALMOCHF-UHFFFAOYSA-N oxolan-3-ylmethanol Chemical compound OCC1CCOC1 PCPUMGYALMOCHF-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000001388 picenyl group Chemical group C1(=CC=CC2=CC=C3C4=CC=C5C=CC=CC5=C4C=CC3=C21)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000002694 regional anesthesia Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Chemical group 0.000 description 1
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical group O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008117 stearic acid Chemical class 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical class OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002813 thiocarbonyl group Chemical class *C(*)=S 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Definitions
- the invention relates to organic chemistry and in particular to prodrugs and pharmaceutical formulations.
- Propofol (2,6-diisopropylphenol) is a low molecular weight phenol (178.27) with a low melting point that is widely used as an intravenous sedative-hypnotic agent in the induction and maintenance of anesthesia or sedation in humans and other mammals.
- anesthetic Among its advantages as an anesthetic are rapid onset of anesthesia, rapid clearance, and minimal side effects (Baker et al, Anesthesiology 2005, 103, 860-876).
- Propofol has a broad range of biological and medical applications, being reported to be an anti-emetic, an anti-epileptic, an anti-pruritic, and an antimigraine agent. Propofol has also been used as an antioxidant.
- Propofol is slightly soluble in water, has a pKa of 11, and its octano I/water partition coefficient is 6761 : 1 at a pH of 6-8.5. Therefore, it is formulated in oil-in-water emulsions for injectables (Diprivan®, Astra-Zeneca), with emulsif ⁇ ers such as the lecithin mixture Intralipid®.
- propofol prodrugs have also been proposed in order to improve propofol aqueous solubility.
- Prodrugs of propofol have been reported (e.g., Gallop et al, WO2005/023204; Gibiansky et al., WO2007008869; Rogers et al., UA 76 802 C2; Wozniak et al., CA 2 548 216 Al).
- Patent applications WO199958555 and WO2002013810 disclose methods for treating or preventing migraine headaches using propofol prodrugs, such as mono(propofol)phosphate and di(propofol)phosphate, that are much more soluble in water than propofol and that metabolize in vivo into the active propofol.
- propofol prodrugs such as mono(propofol)phosphate and di(propofol)phosphate
- propofol formulations are in injectable form due to the poor oral bioavailability of propofol.
- Injectable drug delivery systems are less conveninent than oral formulations due to several factors, particularly because they require assistance for administration, the painful application thereof, the extemporaneous preparation that such formulations usually require, or otherwise, the need for special storage at cool temperatures that readily prepared injectables demand.
- Such propofol forms and formulations must be safe, i.e. having minimal side effects, and with appropriate pharmacokinetic profiles.
- the present invention is based on the surprising finding that propofol can be derivatized, onto the phenolic group, with specific phosphonic moieties which show completely different solubility properties in certain pharmaceutically acceptable solvents, and improved oral bioavailability.
- the specific phosphonic moieties of the phosphonyl-containing propofol derivatives of this invention comprise a saturated acyclic, homocyclic or heterocyclic group, or a combination thereof, attached to the phosphorus atom through a linker which may comprise one or more carbonyl or sulfonyl groups.
- the present invention provides oral formulations as well as injectable forms of propofol.
- the term ' ' aryl ' ' designates any mono- or polycyclic aromatic monovalent hydrocarbon group having from 6 to 15 carbon atoms such as, but not limited to, phenyl, naphthyl, anthracenyl, phenanthracyl, fluoranthenyl, chrysenyl, pyrenyl, biphenyl, terphenyl, picenyl, indenyl, biphenyl, indacenyl, benzocyclobutenyl, benzocyclooctenyl and the like.
- phenyl ring is fused to a C 4 -S cycloalkyl group (the latter being as defined below) such as, for instance, indanyl, tetrahydronaphthyl, fluorenyl and the like.
- a phenyl ring is fused to one or more saturated or unsaturated heterocyclic rings each containing at least one heteroatom selected from the group consisting of nitrogen, oxygen and sulfur such as, for instance, benzothienyl, thianthrenyl, chromenyl, xanthenyl, phenoxathiinyl, benzofuranyl, isobenzofuranyl, indolyl, isoindolyl, indazolyl, quinolyl, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, carbolinyl, acridinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, chromanyl, isochromanyl, phenoxazinyl, phenothiazinyl, isoindolinyl, benzoiso
- Each of said aryl groups may be optionally substituted, in particular at the ortho, meta and/or para positions of the phenyl ring, with one or more substituents independently selected from the group consisting of chloro, bromo, iodo, trifluoromethyl, trifluoromethoxy, Ci_6 alkyl and Ci_6 alkoxy (the latter being as defined below) such as for instance bromochlorophenyl, bromotolyl, chlorotolyl, iodotolyl, dibromophenyl, dichlorophenyl, diiodophenyl, dimethoxyphenyl, dimethylphenyl (xylyl), diisopropylphenyl, 2,4,6-trimethylphenyl (mesityl), trimethoxyphenyl and the like.
- substituents independently selected from the group consisting of chloro, bromo, iodo, trifluoromethyl, trifluoromethoxy, Ci_6 alkyl and
- Ci_4 alkyl refers to a straight or branched chain saturated acyclic hydrocarbon monovalent group having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, n-butyl, 1-methylethyl (isopropyl), 2-methylpropyl (isobutyl) and 1,1-dimethylethyl (tert-buty ⁇ ).
- Ci_6 alkyl refers to straight and branched chain saturated acyclic hydrocarbon monovalent groups having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, n-butyl, 1-methylethyl (isopropyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), 2-methyl-butyl, n-pentyl, dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, and the like.
- C 1-10 alkyl and “Ci_2o alkyl” similarly refer to straight and branched chain saturated acyclic hydrocarbon monovalent groups having from 1 to 10 and from 1 to 20 carbon atoms, respectively, thus including those already listed for Ci_6 alkyl and the like, as well as n-octyl, n-nonyl, n-decyl, for “Ci_io alkyl", and n-undecyl, n-dodecyl, n-tetradecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n- pentadecyl, n-nonadecyl and 1-eicosanyl for "Ci_2o alkyl”.
- Ci_6alkoxy refers to substituents wherein a carbon atom of a Ci_6 alkyl group (such as defined herein), is attached to an oxygen atom through a single bond such as, but not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, isopropoxy, sec-butoxy, tert-butoxy and isopentoxy.
- C3_ i 2 cycloalkyl means a mono- or polycyclic saturated hydrocarbon monovalent radical having from 3 to 12 carbon atoms, such as for instance cyclopropyl, eye Io butyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cycloundecyl, cyclododecyl and the like, or a C 7 -Io polycyclic saturated hydrocarbon monovalent radical having from 7 to 10 carbon atoms such as, for instance, norbornyl, fenchyl, trimethyltricycloheptyl or adamantyl.
- saturated heterocyclyl refers to a mono- or polycyclic, saturated monovalent hydrocarbon group having from 2 up to 15 carbon atoms and including one or more heteroatoms in one or more heterocyclic rings, each of said rings having from 3 to 10 atoms (and optionally further including one or more heteroatoms attached to one or more carbon atoms of said ring, for instance in the form of a carbonyl or thiocarbonyl or selenocarbonyl group, and/or to one or more heteroatoms of said ring, for instance in the form of a sulfone, sulfoxide, N-oxide, phosphate, phosphonate or selenium oxide group), each of said heteroatoms being independently selected from the group consisting of nitrogen, oxygen, sulfur, selenium and phosphorus; representative but non-limiting examples within this group are 1,2-oxathiolanyl, oxiranyl, aziridiny
- halogen refers to any one of fluoro, chloro, bromo and iodo.
- the present invention relates to a class of phosphonyl-containing propofol derivatives represented by the structural formula (I): and the salts and stereoisomers thereof, wherein:
- - p is an integer from 1 to 8
- each R 3 and each R 4 is independently selected from the group consisting of Ci_ 2 oalkyl, C 3 . 1 2 alkyl, C3-i2cycloalkyl-Ci_4alkyl, saturated heterocyclyl and saturated heterocyclyl-Ci_ 4alkyl, and - X and Y are each independently C or S(O),
- - Z is selected from the group consisting of O, S(O) and NR 5 ,
- - W is selected from the group consisting of halogen, OH, S(O)H and 0 " M + wherein M + is a monovalent cation (such as, but not limited to, an alkali metal cation, e.g. Na + or K + ); and
- R 5 is selected from the group consisting of hydrogen and C 1-10 alkyl.
- a useful embodiment is a phosphonyl-containing phenolic derivative represented by the structural formula (I) wherein R 3 and R 4 are independently -(CH 2 ) n -CH 3 wherein n is an integer from 8 to 16.
- - p is an integer from 2 to 3;
- each R 3 and each R 4 is independently selected from the group consisting of Ci_ 2 oalkyl and C 3 . 1 2 alkyl;
- - X and Y are each independently C;
- - W is selected from the group consisting of halogen and OH.
- radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable.
- each definition is independent. Radicals used in the definitions of the variables include all possible isomers unless otherwise indicated. For instance pentyl includes 1 -pentyl, 2-pentyl and 3 -pentyl.
- the compounds of formula (I) may have several centers of chirality, particularlyin respect to the L group when branched, and exist as stereochemically isomeric forms.
- stereochemically isomeric forms as used herein defines all the possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess. With reference to the instances where (R) or (S) is used to designate the absolute configuration of a chiral atom within a substituent, the designation is done taking into consideration the whole compound and not the substituent in isolation. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereo chemically isomeric forms, which said compound might possess.
- Said mixture may contain all diastereomers and enantiomers of the basic molecular structure of said compound. All stereo chemically isomeric forms of the compounds of the present invention both in pure form or mixed with each other are intended to be embraced within the scope of the present invention.
- stereoisomerically pure concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i.e. minimum 80% of one isomer and maximum 20% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to 100% and most in particular having a stereoisomeric excess of 97% up to 100%.
- enantiomerically pure and “diastereomerically pure” should be understood in a similar way, but then having regard to the enantiomeric excess, and the diastereomeric excess, respectively, of the mixture in question.
- Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures.
- enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphorsulfonic acid.
- enantiomers may be separated by chromatographic techniques using chiral stationary phases.
- Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occur stereospecifically.
- said compound will be synthesized by stereospecif ⁇ c methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
- the diastereomeric racemates of the compounds of formula (I) can be obtained separately by conventional methods.
- Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.
- the present invention is also intended to include all isotopes of atoms occurring on the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include tritium and deuterium.
- Isotopes of carbon include C-B and C-14.
- salts of the compounds of formula (I) are those wherein the counter-ion is pharmaceutically acceptable, which salts can be referred to as pharmaceutically acceptable acid and base addition salts.
- salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not, are included within the ambit of the present invention.
- the pharmaceutically acceptable acid and base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and base addition salt forms that the compounds of formula (I) are able to form.
- the pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid in an anion form.
- Appropriate anions comprise, for example, acetate, benzenesulfonate , benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsyiate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate,
- the compounds of formula (I) containing an acidic proton may also be converted into their nontoxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases in a cation form.
- Appropriate basic salts comprise those formed with organic cations such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, and the like; and those formed with metallic cations such as aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and the like.
- said salt forms can be converted by treatment with an appropriate acid into the free form.
- Some of the compounds of formula (I) may also exist in their tautomeric form. Such forms, although not explicitly indicated in the above formula, are intended to be included within the scope of the present invention.
- the present invention relates to various methods for making the phosphonyl-containing propofol derivatives defined in any one of the above embodiments, in particular wherein the linker L may have any one of the above meanings. These methods usually proceed in at least two steps.
- phosphonyl-containing propofol derivatives represented by the structural formula (I) wherein L is a single bond can be made according to the following sequence of steps:
- phosphorus oxyhalide e.g. phosphorus oxychloride or phosphorus oxybromide
- a catalytic amount of a tertiary amine such as, but not limited to, triethylamine
- R 3 is preferably selected from the group consisting of Ci_ 2 oalkyl, C 3 _i 2 cycloalkyl, C 3 _i 2 cycloalkyl-Ci_ 4 alkyl, saturated heterocyclyl and saturated heterocyclyl-Ci_ 4 alkyl, in particular R 3 may be -(CH 2 ) n -CH 3 wherein n is an integer preferably from 8 to 16.
- Suitable mono-alcohols R 3 OH for use in the first production methods of the present invention include, but are not limited to: - acyclic, linear or branched, mono-alcohols such as, but not limited to, methanol, ethanol, n- propanol, n-butanol, n-pentanol, n-hexanol, n-heptanol, 2,2-dimethyl-3-pentanol, 2,3- dimethyl-3-pentanol, 2,4-dimethyl-3-pentanol, 4,4-dimethyl-2-pentanol, n-octanol, n- nonanol, n-decanol, n-decanol, n-undecanol, n-dodecanol, n-tridecanol, n-tetradecanol, n- pentadecanol, n-hexadecano
- - homocyclic mono-alcohols such as, but not limited to, cyclobutanol, cyclopentanol, 1- methylcyclopentanol, 2-methylcyclopentanol, 3-methyl-cyclopentanol, cyclohexanol, 1- methylcyclohexanol, 2-methylcyclohexanol, 3-methylcyclohexanol, 4-methylcyclohexanol, 2-te/t-butylcyclohexanol, 4-te/t-butylcyclohexanol, 1-adamantanol, 2-adamantanol, 1,3,3- trimethyl-2-norbornanol, cycloheptanol, cyclooctanol, and cyclododecanol;
- acyclic-homocyclic mono-alcohols such as, but not limited to, cyclopropanemethanol, cyclobutanemethanol, cyclopentanemethanol, cyclohexylmethanol, 2-cyclohexylethanol, 3-cyclohexyl- 1 -propanol, 3-cyclopentyl- 1 -propanol, cycloundecanemethanol, 2-norbornanemethanol, 1-adamanemethanol, 1-adamaneethanol, cycloheptanemethanol, and cyclododecanemethanol;
- heterocyclyl mono-alcohols such as, but not limited to, 4-hydroxypiperidine, 3- hydroxypiperidine, 3 -hydroxy- 1-methylpiperidine, 4-hydroxy-l-methylpiperidine, 1-methyl- 3-pyrrolidinol, tetrahydro-4H-pyran-4-ol and 3-quinuclidinol ;
- - mixed acyclic-saturated heterocyclic mono-alcohols such as, but not limited to, l-(2- hydro xyethyl)piperazine, 4-(2-hydroxyethyl)morpholine, l-(2-hydroxyethyl)pyrrolidine, 1- methyl-2-pyrrolidineethanol, (S)- 1 -methyl-2-pyrrolidinemethanol, (2- hydroxyethyl)piperidine, (hydro xymethyl)-piperidine, tetrahydropyran-2-methano 1, tetrahydro-3-furanmethanol, tetrahydrofurfuryl alcohol, dihydro-5-(hydroxymethyl)-2(3H)- furanone and 1-aziridineethanol.
- phosphonyl-containing propofol derivatives represented by the structural formula (I), wherein L is -(C ⁇ 2 ) P -O-X(O)-, X is C or S(O) and p is an integer from 1 to 8, can be made according to the following sequence of steps:
- R 3 is preferably selected from the group consisting of Ci_ 2 oalkyl, C 3 - 12 CVC Io alkyl, C 3 -i 2 cycloalkyl-Ci_ 4 alkyl, saturated heterocyclyl and saturated heterocyclyl-Ci_ 4 alkyl, in particular R 3 may be -(CH 2 ) n -CH 3 wherein n is an integer preferably from 8 to 16), with a linear acyclic diol represented by the structural formula HO-(CH 2 ) P -OH wherein p is an integer from 1 to 8, to form an intermediate represented by the structural formula R 3 X(O)O-(CH 2 ) P -OH; and - this intermediate R X(0)0-(CH 2 ) p -0H is then reacted with a phosphorus oxyhalide intermediate with the structural formula (II) (
- the second method of the present invention may further comprise a final step of transforming, e.g. through hydrolysis, the phosphonyl-containing propofol derivative wherein W is a halogen into the corresponding phosphonyl-containing propofol derivative wherein W is hydroxyl.
- Suitable acyclic diols for use in the second production method of the present invention include, but are not limited to, ethylene glycol, 1,3-propanediol, 1,4-butanediol, 1,5-pentanediol, 2,4- dimethyl-2,4-pentanediol, 2,5-dimethyl-2,5-hexanediol, 1,6-hexanediol, and 1,8-octanediol.
- Suitable carbonyl chlorides R 3 COCl for use in the second production method of the present invention include, but are not limited to, those wherein R 3 is preferably selected from the group consisting of Ci_ 2 oalkyl, C 3 _i 2 cycloalkyl, C 3 _i 2 cycloalkyl-Ci_ 4 alkyl, saturated heterocyclyl and saturated heterocyclyl-C ⁇ alkyl, in particular R 3 may be -(CH 2 ) n -CH 3 wherein n is an integer preferably from 8 to 16. Particularly suitable examples thereof include:
- alkanoyl chlorides such as, but not limited to, acetyl chloride, propionyl chloride, butyryl chloride, isobutyryl chloride, valeryl chloride, isovaleryl chloride, pivaloyl chloride, capryloyl chloride, nonanoyl chloride, decanoyl chloride, lauroyl chloride, myristoyl chloride, palmitoyl chloride, stearoyl chloride and the like;
- alkanoyl chlorides such as, but not limited to, acetyl chloride, propionyl chloride, butyryl chloride, isobutyryl chloride, valeryl chloride, isovaleryl chloride, pivaloyl chloride, capryloyl chloride, nonanoyl chloride, decanoyl chloride, lauroyl chloride, myristoyl chloride, palmitoyl chloride, stearoyl chloride and the like;
- - homocyclic carbonyl chlorides including cycloalkanoyl chlorides such as, but not limited to, cyclobutanecarbonyl chloride, cyclopentanecarbonyl chloride, cyclohexanecarbonyl chloride,
- - mixed acyclic-homocyclic carbonyl chlorides including cycloalkyl-alkanoyl chlorides such as, but not limited to, cyclohexylacetyl chloride, cyclopentylacetyl chloride, 2- norbornaneacetyl chloride, 1-adamantane-carbonyl chloride and the like; - saturated heterocyclyl carbonyl chlorides such as, but not limited to, 4-morpholinylcarbonyl chloride, 1-pyrrolidinecarbonyl chloride, tetrahydro-2-furancarbonyl chloride and the like; and
- - mixed acyclic-heterocyclic carbonyl chlorides including saturated heterocyclyl-alkanoyl chlorides such as, but not limited to, 3-(l,3-dioxan-2-yl)-propionyl chloride and 3-(l,3- dioxan-2-yl)-2-methylpropionyl chloride.
- Suitable sulfonyl chlorides R 3 SO 2 Cl for use in the second production method of the present invention include, but are not limited to, the following: - acyclic, linear or branched, sulfonyl chlorides including alkanesulfonyl chlorides such as, but not limited to, methanesulfonyl chloride, ethanesulfonyl chloride, 1-propanesulfonyl chloride, 1-butanesulfonyl chloride, 1-hexanesulfonyl chloride, 1-octanesulfonyl chloride, 1- decanesulfonyl chloride and the like;
- alkanesulfonyl chlorides such as, but not limited to, methanesulfonyl chloride, ethanesulfonyl chloride, 1-propanesulfonyl chloride, 1-butanesulfonyl chloride, 1-hexanesulfonyl chloride
- - homocyclic sulfonyl chlorides including cycloalkanesulfonyl chlorides such as, but not limited to, cyclopentanesulfonyl chloride, cyclohexanesulfonyl chloride and the like;
- heterocyclyl sulfonyl chlorides such as, but not limited to, 4-morpholinesulfonyl chloride, pyrrolidine- 1 -sulfonyl chloride and the like.
- phosphonyl-containing propofol derivatives represented by the structural formula (I), wherein L is -(CH 2 ) P -O- and p is an integer from 1 to 8, can be made according to the following sequence of steps:
- R 3 reacting a saturated acyclic, homocyclic or heterocyclic mono-alcohol R 3 OH wherein R 3 is preferably selected from the group consisting of Ci_ 2 oalkyl, C3_i 2 cycloalkyl, C3_i 2 cycloalkyl- Ci_ 4 alkyl, saturated heterocyclyl and saturated heterocyclyl-Ci_ 4 alkyl, in particular R 3 may be -(CH 2 ) n -CH 3 wherein n is an integer preferably from 8 to 16, with an ⁇ -halo (preferably ⁇ -bromo) ⁇ -alcohol represented by the structural formula Q-(CH 2 ) P -OH wherein p is an integer from 1 to 8 and Q is a halogen (preferably bromo); this reaction may take place in the presence of sodium hydride and a suitable solvent such as (but not limited to) tetrahydrofuran and results into a substituted alcohol intermediate represented by the structural formula R 3 O-(CH 2 )
- the third method of the present invention may further comprise a final step of transforming, e.g. through hydrolysis, the phosphonyl-containing propofol derivative wherein W is a halogen into the corresponding phosphonyl-containing propofol derivative wherein W is hydroxyl.
- FIG. 3 A An illustrative embodiment of the third production method of the present invention, wherein R is a linear alkyl group -(CH 2 ) n -CH 3 , and p is 3, is schematically shown in figure 3 A (first step) and figure 3 B (second step and hydrolysis step).
- Suitable mono-alcohols R 3 OH for use in the third production method of the present invention are the same as previously detailed with respect to the first production method of the present invention.
- ⁇ -bromo alcohols are preferred.
- the type of alkyl group present in said alcohols is not important but may be limited in practice by commercial availability.
- R 4 is selected from the group consisting of Ci_2oalkyl, C3-i2alkyl, C3-i2cycloalkyl-Ci_4 alkyl, saturated heterocyclyl and saturated heterocyclyl-Ci_4 alkyl, and
- X or Y are each independently C or S(O), can be made according to the following sequence of steps: reacting 1,2,3-propanetriol is reacted with one or more carbonyl chlorides R'COCl and/or sulfonyl chlorides R 5 SO 2 Cl (wherein R' is defined in the same meaning as R 3 and R 4 ) to form a R 3 ,R 4 -containing l,3-di(acyloxy)-propan-2-ol and/or a R 3 ,R 4 -containing l,3-di(sulfoxy)- propan-2-ol intermediate; and reacting the latter l,3-di(acyloxy)-propan-2-ol or l,3-di(sulfoxy)-propan-2-ol intermediate, with a phosphorus oxyhalide intermediate with the structural formula (II) wherein Q is a halogen (preferably chloro or bromo),
- the fourth method of the present invention may further comprise a final step of hydro lysing the phosphonyl-containing propofol derivative wherein W is a halogen into the corresponding phosphonyl-containing propofol derivative, wherein W is hydroxyl.
- R 3 differs from R 4 and/or X differs from Y) by dividing the first step into two successive sub-steps wherein the R 3 -containing moiety and the R 4 -containing moiety are introduced in each sub-step, respectively, by adding different carbonyl chlorides and/or sulfonyl chlorides.
- This alternative method may however require that a hydroxyl group of 1,2,3-propanetriol is first protected by a conventional hydro xy-protecting group before performance of the first sub-step and then deprotected before performance of the second sub-step to avoid the formation of undesirable by-products.
- both R 3 and R 4 , and both X and Y may independently be selected at will in the structural formula (I), depending upon the easiness of each sub-step and the desirable physical characteristics of the propofol derivative to be produced.
- Suitable carbonyl chlorides R 3 COCl and R 4 COCl, and suitable sulfonyl chlorides R 3 SO 2 Cl and R 4 SO 2 Cl for use in the fourth method of this invention are the same as previously detailed with respect to the second production method of the present invention.
- FIG. 4 A An illustrative embodiment of the fourth production method of the present invention, wherein R 3 and R > 4 are both tridecyl groups and X and Y are both C, is schematically shown in figure 4 A (first step) and figure 4B (second step and hydrolysis step).
- this derivative can be converted into a monovalent salt, i.e. a corresponding derivative wherein W is 0 " M + wherein M + is a monovalent cation (such as, but not limited to, an alkali metal cation, e.g. Na + or K + ), by using techniques well known to the skilled person.
- a monovalent salt i.e. a corresponding derivative wherein W is 0 " M + wherein M + is a monovalent cation (such as, but not limited to, an alkali metal cation, e.g. Na + or K + ), by using techniques well known to the skilled person.
- reaction conditions e.g. temperature, reaction time, molar ratio between the reactants, solvent of choice and the like, and the type of extraction and/or purification methods generally suitable for each synthetic step in any of the four above described production methods of the present invention are well known to the skilled person. If necessary for optimisation of the reaction yield, a reaction step may be performed in the presence of an effective amount of a catalyst well known to the skilled person.
- the resulting compounds may be optionally converted into a pharmaceutically acceptable salt or vice versa according to the methods known by the skilled in the art.
- compounds of formula (I) may be converted into each other following art-known functional group transformation reactions.
- amino groups may be N-alkylated, nitro groups reduced to amino groups, a halo atom may be exchanged for another halo.
- Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.
- the compounds of formula (I) may be obtained as racemic mixtures of enantiomers, which can be separated from one another following art-known resolution procedures.
- the racemic compounds of formula (I) that are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid.
- An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase.
- Said pure stereochemical ⁇ isomeric forms may also be derived from the corresponding pure stereo chemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecif ⁇ cally.
- said compound may be synthesized by stereospecific methods of preparation. These methods may advantageously employ enantiomerically pure starting materials.
- the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a propofol derivative according to any of the above-referred embodiments, and one or more pharmaceutically acceptable excipients.
- compositions according to this invention may be administered orally or in any other suitable fashion.
- the preparation may have the form of a tablet, aqueous dispersion, dispersable powder or granule, emulsion, hard or soft capsule, syrup, elixir or gel.
- the dosing forms may be prepared using any method known in the art for manufacturing these pharmaceutical compositions and may comprise as additives sweeteners, flavoring agents, coloring agents, preservatives and the like.
- Carrier materials and excipients are detailed hereinbelow and may include, inter alia, calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, binding agents and the like.
- the pharmaceutical composition of this invention may be included in a gelatin capsule mixed with any inert solid diluent or carrier material, or has the form of a soft gelatin capsule, in which the ingredient is mixed with a water or oil medium.
- Aqueous dispersions may comprise the biologically active composition or combined preparation in combination with a suspending agent, dispersing agent or wetting agent.
- Oil dispersions may comprise suspending agents such as a vegetable oil. Rectal administration is also applicable, for instance in the form of suppositories or gels.
- injection e.g. intramuscularly or intraperiteneously
- injection is also applicable as a mode of administration, for instance in the form of injectable aqueous solutions or dispersions, depending upon the disorder to be treated and the condition of the patient.
- aqueous solutions include, for example, water, saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions and the like.
- the pharmaceutical injectable compositions may contain one or more pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions or to improve stability, appearance or ease of administration, such as buffering agents, tonicity adjusting agents, wetting agents, detergents and the like.
- Additives can also include additional active ingredients such as bactericidal agents, or stabilising agents.
- the aqueous solution of the invention may contain one or more additives selected from the group consisting of sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate and triethanolamine oleate. These aqueous compositions can be sterilised by conventional, well-known sterilisation techniques, or can be sterile filtered.
- aqueous solutions can be packaged for use as such, or can be lyophilised, the lyophilised preparation being combined with a sterile aqueous solution prior to administration.
- aqueous solutions are appropriate for injection and, in particular, for intravenous injection.
- Intravenous injection is a particularly appropriate means of delivery for using a propofol derivative of this invention as an anti-migraine agent.
- the intravenous solution can include detergents and emulsifiers such as lipids.
- Aqueous solutions also are useful for oral and enteral and other routes of administration as tonics, and for administration to mucous or other membranes as, e.g., nose or eye drops.
- the aqueous composition of this invention may contain the phenol derivative in an amount from about 1 mg/ml to about 100 mg/ml, preferably from about 5 to 20 mg/ml.
- Suitable dosages of the pharmaceutical compositions of the present invention, in particular injectable formulations, may range from 0.05 to 100 mg/Kg.
- the pharmaceutical composition of the present invention is in the form of an injectable.
- the injectable is administered intravenously, intramuscularly, subcutaneously, intraperitoneally, intra-articularly, intralesionally, intraventricular ⁇ , by spinal injection, by intraosseous infusion, or transdermally.
- pharmaceutically acceptable carrier or excipient as used herein in relation to any type of pharmaceutical compositions means any material or substance with which the active principle, i.e. the propofol derivative of this invention, may be formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and/or to facilitate its storage, transport or handling without impairing its effectiveness.
- the pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e. the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, pellets or powders.
- Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art. There is no particular restriction to their selection within the present invention although special attention may be paid to the selection of suitable carrier combinations that can assist in properly formulating the propofol derivative in view of the expected time release profile.
- Suitable pharmaceutical carriers include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying or surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals.
- compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, dissolving, spray-drying, coating and/or grinding the active ingredients, in a one-step or a multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents.
- the compositions may also be prepared by micronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 ⁇ m, namely for the manufacture of microcapsules for controlled or sustained release of the biologically active agent.
- Suitable surface-active agents to be used in the pharmaceutical compositions of the present invention are non-ionic, cationic and/or anionic surfactants having good emulsifying, dispersing and/or wetting properties.
- Suitable anionic surfactants include both water-soluble soaps and water-soluble synthetic surface-active agents.
- Suitable soaps are alkaline or alkaline-earth metal salts, unsubstituted or substituted ammonium salts of higher fatty acids (C 10 -C 22 ), e.g. the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures obtainable form coconut oil or tallow oil.
- Synthetic surfactants include sodium or calcium salts of polyacrylic acids; fatty sulphonates and sulphates; sulphonated benzimidazole derivatives and alkylarylsulphonates.
- Fatty sulphonates or sulphates are usually in the form of alkaline or alkaline-earth metal salts, unsubstituted ammonium salts or ammonium salts substituted with an alkyl or acyl radical having from 8 to 22 carbon atoms, e.g.
- Suitable sulphonated benzimidazole derivatives preferably contain 8 to 22 carbon atoms.
- alkylarylsulphonates are the sodium, calcium or alcanolamine salts of dodecylbenzene sulphonic acid or dibutyl-naphthalenesulphonic acid or a naphtalene-sulphonic acid/formaldehyde condensation product.
- corresponding phosphates e.g. salts of phosphoric acid ester and an adduct of p-nonylphenol with ethylene and/or propylene oxide, or phospholipids.
- Suitable phospholipids for this purpose are the natural (originating from animal or plant cells) or synthetic phospholipids of the cephalin or lecithin type such as e.g.
- phosphatidylethanolamine phosphatidylserine, phosphatidylglycerine, lysolecithin, cardiolipin, dioctanyl-phosphatidylcholine, dipalmitoylphoshatidylcholine and their mixtures.
- Suitable non-ionic surfactants include polyethoxylated and polypropoxylated derivatives of alkylphenols, fatty alcohols, fatty acids, aliphatic amines or amides containing at least 12 carbon atoms in the molecule, alkylarenesulphonates and dialkylsulphosuccinates, such as polyglycol ether derivatives of aliphatic and cycloaliphatic alcohols, saturated and unsaturated fatty acids and alkylphenols, said derivatives preferably containing 3 to 10 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenol.
- non-ionic surfactants are water-soluble adducts of polyethylene oxide with poylypropylene glycol, ethylenediamino -polypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethyleneglycol ether groups and/or 10 to 100 propyleneglycol ether groups.
- Such compounds usually contain from 1 to 5 ethyleneglycol units per propyleneglycol unit.
- non-ionic surfactants are nonylphenol-polyethoxyethanol, castor oil poly-glycolic ethers, polypropylene/polyethylene oxide adducts, tributylphenoxy-polyethoxyethanol, polyethyleneglycol and octylphenoxypolyethoxyethanol.
- Fatty acid esters of polyethylene sorbitan such as polyoxyethylene sorbitan trioleate
- glycerol glycerol
- sorbitan sucrose and pentaerythritol
- pentaerythritol are also suitable non-ionic surfactants.
- Suitable cationic surfactants include quaternary ammonium salts, preferably halides, having four hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy; for instance quaternary ammonium salts containing as N-substituent(s) at least one Cs-C 22 alkyl radical (e.g. cetyl, lauryl, palmityl, myristyl, oleyl and the like) and, as further substituents, unsubstituted or halogenated lower alkyl, benzyl and/or hydroxy-Ci_4 alkyl radicals.
- quaternary ammonium salts preferably halides, having four hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy
- quaternary ammonium salts containing as N-substituent(s) at least one Cs-C 22 alkyl radical (e.g. cet
- Structure-forming, thickening or gel- forming agents may be included into the pharmaceutical compositions and combined preparations of the invention.
- Suitable such agents are in particular highly dispersed silicic acid, such as the product commercially available under the trade name Aerosil; bentonites; tetraalkyl ammonium salts of montmorillonites (e.g. products commercially available under the trade name Bentone), wherein each of the alkyl groups may contain from 1 to 20 carbon atoms; cetostearyl alcohol and modified castor oil products (e.g. the product commercially available under the trade name Antisettle).
- Gelling agents which may be included into the pharmaceutical compositions of the present invention include, but are not limited to, cellulose derivatives such as carboxymethylcellulose, cellulose acetate and the like; natural gums such as arabic gum, xanthum gum, tragacanth gum, guar gum and the like; gelatin; silicon dioxide; synthetic polymers such as carbomers, and mixtures thereof.
- Gelatin and modified celluloses represent a preferred class of gelling agents.
- additives such as magnesium oxide; azo dyes; organic and inorganic pigments such as titanium dioxide; UV-absorbers; stabilisers; odor masking agents; viscosity enhancers; antioxidants such as, for example, ascorbyl palmitate, sodium bisulfite, sodium metabisulfite and the like, and mixtures thereof; preservatives such as, for example, potassium sorbate, sodium benzoate, sorbic acid, propyl gallate, benzylalcohol, methyl paraben, propyl paraben and the like; sequestering agents such as ethylene-diamine tetraacetic acid; flavoring agents such as natural vanillin; buffers such as citric acid and acetic acid; extenders or bulking agents such as silicates, diatomaceous earth, magnesium oxide or aluminum oxide; densification agents such as magnesium salts; and mixtures thereof.
- additives such as magnesium oxide; azo dyes; organic and inorganic pigments such as titanium dioxide; UV-absorb
- Control release compositions may thus be achieved by selecting appropriate polymer carriers such as for example polyesters, polyamino-acids, polyvinyl-pyrrolidone, ethylene-vinyl acetate copolymers, methylcellulose, carboxy-methylcellulose, protamine sulfate and the like.
- the rate of drug release and duration of action may also be controlled by incorporating the active agent into particles, e.g. microcapsules, of a polymeric substance such as hydrogels, polylactic acid, hydroxymethylcellulose, polymethylmethacrylate and the other above-described polymers.
- Such methods include colloid drug delivery systems like liposomes, microspheres, microemulsions, nanoparticles, nanocapsules and so on.
- the pharmaceutical composition of this invention may also require protective coatings.
- compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation thereof.
- Typical carriers for this purpose therefore include biocompatible aqueous buffers, ethanol, glycerol, propylene glycol, polyethylene glycol, complexing agents such as cyclodextrins and the like, and mixtures thereof in any suitable proportions.
- the selected propofol derivative active agent may be administered topically, in an ointment, gel or the like, or transdermally, using a conventional transdermal drug delivery system.
- the compounds of the present invention are useful because they possess pharmacological activity in animals, including humans.
- the compounds are useful as anesthetic, sedative-hypnotic, or as anti-migraine agent.
- they are useful in inducing and maintaining general anesthesia, initiation and maintenance of Monitored Anesthesia Care (MAC) sedation, initiation and maintenance of Intensive Care Unit (ICU) sedation in intubated mechanically ventilated subjects, combined sedation and regional anesthesia, cardiac anesthesia, neuroanesthesia.
- MAC Monitored Anesthesia Care
- ICU Intensive Care Unit
- They can also be used in the treatment or prevention of migraine headache, for reducing post-operative nausea and vomiting, for providing anti-emetic activity, for treating refractory status epilepticus, or for use as an anti-convulsant in a mammal.
- the compounds of the present invention, pharmaceutically acceptable salts thereof, or any subgroup thereof may therefore be used as a medicament.
- Said use as a medicament or method of treatment comprises the systemic administration to a subject in need thereof, of an amount effective to induce or maintain anesthesia, to treat or prevent migraine headache, to reduce post- operative nausea and vomiting, for providing anti-emetic activity, for treating refractory status epilepticus, or for use as an anti-convulsant in a mammal
- the present invention also relates to the use of the present compounds, pharmaceutically acceptable salts thereof, or any subgroup thereof for the manufacture of a medicament for the induction or maintenance of anesthesia, for the treatment or prevention of migraine headache, to reduce post-operative nausea and vomiting, for providing anti-emetic activity, for treating refractory status epilepticus, or for use as an anti-convulsant in a mammal.
- the present invention further relates to the compound of formula (I), pharmaceutically acceptable salts thereof, or any subgroup thereof, for use as an anesthetic agent, sedative-hypnotic, or as anti-migraine agent.
- the present invention relates to a a method of induction or maintenance of anesthesia, which comprises administering an effective amount of a compound according to any one of the embodiments herein, to a patient in need of such induction or maintenance.
- the present invention relates to a method of extending the release of propofol, which comprises converting propofol into a compound of formula (I), a pharmaceutically acceptable salt thereof, or any subgroup thereof.
- R 3 and R 4 are a tridecyl group each, as schematically shown in figures 4A and 4B and following the principles of the fourth production method of the present invention, as outlined herein-above.
- Table 1 provides the solubility data at 25°C, expressed in mg/ml, of the final propofol derivatives produced and characterised in examples 1-4 respectively.
- the solubility determination method used was as follows: a suspension of 6 mg of the relevant propofol derivative in 500 ⁇ l of the relevant pharmaceutical solvent was rotatively shaken for 24 hours at 800 rpm at 25°C. The saturated propofol derivative solution was filtered (0.45 ⁇ m) and 150 ⁇ l of the filtrate was diluted in dimethylsulfoxide (50 ⁇ l DMSO). This solution was assayed, each assay being carried out in three-fold, by measurement with Liquid Chromatography-Mass Spectrometry (LCMS, l ⁇ l and 10 ⁇ l injection).
- LCMS Liquid Chromatography-Mass Spectrometry
- Miglyol 812 b 28.1 7.7 0.0 4.3 a an emulsifying agent obtained by reacting 45 moles of ethylene oxide with 1 mole of hydrogenated castor oil, commercially available from BASF AG (Germany).
- b a caprylic/capric acid triglyceride, commercially available from SASOL GmbH (Germany).
- Example 6 Chemical stability of a propofol derivative wherein L is a single bond in pharmaceutical solvents
- Table 2 provides the chemical stability data in some pharmaceutical solvents, expressed as the weight percentage of the final propofol derivative produced and characterised in example 1 that remained in solution after a certain period of time. The test was carried out twice, and the remaining weight % was determined by Liquid Chromatography-Mass Spectrometry (LCMS).
- LCMS Liquid Chromatography-Mass Spectrometry
- Table 2 shows that at most 9% of the propofol derivative did not remain in the relevant aqueous or hydro xypropyl- ⁇ -cyclodextrin or polyethylene glycol solution after 14 days.
- Example 7 Chemical stability in pharmaceutical solvents of a propofol derivative wherein L is -(CHz) 2 -O-C(O)-
- Table 3 provides the chemical stability data in some pharmaceutical solvents, expressed as the weight percentage of the final propofol derivative produced and characterised in example 2 that remained in solution after a certain period of time. The test was carried out twice, and the remaining weight % was determined by Liquid Chromatography-Mass Spectrometry (LCMS).
- LCMS Liquid Chromatography-Mass Spectrometry
- Table 3 shows that at most 3.5% of the propofol derivative did not remain in the relevant aqueous or hydro xypropyl- ⁇ -cyclodextrin or poly-ethylene glycol solution after 14 days.
- Example 8 Chemical stability, in some pharmaceutical solvents, of a propofol derivative wherein L is -(CH 2 ) 3 -O-
- Table 4 provides the chemical stability data in some pharmaceutical solvents, expressed as the weight percentage of the final propofol derivative produced and characterised in example 3 that remained in solution after a certain period of time. The test was carried out twice, and the remaining weight % was determined by Liquid Chromatography-Mass Spectrometry (LCMS).
- LCMS Liquid Chromatography-Mass Spectrometry
- Polyethylene glycol 400 98. 6 98 .0 97. 1 96, .0 95 .2
- Table 4 shows that at most 8% of the propofol derivative did not remain in the relevant aqueous or hydro xypropyl- ⁇ -cyclodextrin or polyethylene glycol solution after 14 days.
- Example 9 Chemical stability of a propofol derivative prepared in Example 4 in pharmaceutical solvents
- Table 5 provides the chemical stability data in some pharmaceutical solvents, expressed as the weight percentage of the final propofol derivative produced and characterised in example 4 that remained in solution after a certain period of time. The test was carried out twice, and the remaining weight % was determined by Liquid Chromatography-Mass Spectrometry (LCMS).
- LCMS Liquid Chromatography-Mass Spectrometry
- Polyethylene glycol 400 97 .2 97. 5 97 .1 97 .0 96 .8
- Table 5 shows that at most 12% of the propofol derivative did not remain in the relevant aqueous or hydro xypropyl- ⁇ -cyclodextrin or polyethylene glycol solution after 14 days.
- Example 10 Pharmacokinetic profile characterization of the propofol derivatives prepared in Examples 1-4
- PK pharmacokinetic
- the rats were fed a standard diet and fastened overnight prior to the administration of the test material.
- Food was provided approximately 4 hours following dosing.
- Prodrugs were dissolved either in mygliol 812, PBS, 0.5% polysorbate 80, 10% vitamin E TPGS or PEG 400.
- the propofol prodrugs were provided separately, and each solution was prepared freshly just before the start of each experiment in a concentration ranging from eq 1.75 - 3.33 mg propofol/mL.
- An overview of the prodrug solutions is given in Table 6. All rats were dosed by oral gavage and the volume was calculated based on the rats body weight 10 minutes prior to administration. Furthermore, during the course of the experiment, the individual body weights of the rats were also recorded at regular time periods.
- Bioanalytical analysis was perfomed using a validated HPLC-MS method which consisted on the quantification of propofol in rat whole-blood by high pressure liquid chromatography and fluorescence detection (excitation wavelength 270 nm, emission wavelength 314 nm). Thymol and 2, 4 -di-tert-butylphenol (DTBP) were used as internal standard.
- DTBP 4 -di-tert-butylphenol
- Non-compartmental PK analysis of the propofol plasma concentrations was performed using WinNonlin Phoenix 6.1 in order to estimate peak plasma concentration and systemic exposure of propofol after the administration of each propofol prodrug. Based on the individual propofol plasma concentration-time data, at least the following PK parameters of propofol were estimated in all rats receiving a dose of propofol prodrug:
- C max peak plasma concentration determined by visual inspection of the data t max time to reach the peak plasma concentration, determined by visual inspection of the data AUC last area under the plasma concentration-time curve from 0 to t hours post dosing, calculated by trapezoidal summation (time t is the time of the last quantifiable concentration Ci ast ).
- AUC a ii AUCi ast . Otherwise, AUC a n will be greater than AUCi ast as it includes the additional area from the last measurable concentration down to zero.
- Au ⁇ AUCt extrapolated to infinity calculated as AUC t + Ci ast / ⁇ z ⁇ z elimination rate constant, determined by linear regression of the terminal points of the In- linear plasma concentration-time curve terminal half-life, defined as 0.693/ ⁇ z
- PK parameters were calculated for propofol after the administration of the propofol prodrugs pepared in Examples 1-4.
- the PK parameters ⁇ SEM obtained with WinNonlin Phoenix 6.1 after the administration of the propofol prodrugs are summarized in Table 7. This table also includes the mean PK parameters ⁇ SEM of propofol after iv and po administration of Diprivan®.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to compounds represented by the structural formula (I), and the salts and stereoisomers thereof, wherein: - L is a linker selected from the group consisting of -(CH2)P-O-, a single bond, formula (IA), -(CH2)1-8-O-X(O)-, and - p is an integer from 1 to 8, - each R3 and each R4 is independently selected from the group consisting of C1-20alkyl, C3-12alkyl, C3-12cycloalkyl-C1-4alkyl, saturated heterocyclyl and saturated heterocyclyl-C1-4alkyl, and - X and Y are each independently C or S(O), - Z is selected from the group consisting of O, S(O) and NR5, - W is selected from the group consisting of halogen, OH, S(O)H and O-M+ wherein M+ is a monovalent cation; and - R5 is selected from the group consisting of hydrogen and C1-10 alkyl. These compounds are useful pharmaceutical agents with improved oral bioavailability.
Description
PROPOFOL PHOSPHONYL DERIVATIVES, SYNTHESIS, AND USE IN ORAL FORMULATIONS
Field of the invention
The invention relates to organic chemistry and in particular to prodrugs and pharmaceutical formulations.
Background of the invention Propofol (2,6-diisopropylphenol) is a low molecular weight phenol (178.27) with a low melting point that is widely used as an intravenous sedative-hypnotic agent in the induction and maintenance of anesthesia or sedation in humans and other mammals. Among its advantages as an anesthetic are rapid onset of anesthesia, rapid clearance, and minimal side effects (Baker et al, Anesthesiology 2005, 103, 860-876). Propofol has a broad range of biological and medical applications, being reported to be an anti-emetic, an anti-epileptic, an anti-pruritic, and an antimigraine agent. Propofol has also been used as an antioxidant.
Propofol is slightly soluble in water, has a pKa of 11, and its octano I/water partition coefficient is 6761 : 1 at a pH of 6-8.5. Therefore, it is formulated in oil-in-water emulsions for injectables (Diprivan®, Astra-Zeneca), with emulsifϊers such as the lecithin mixture Intralipid®.
Alternatively, propofol prodrugs have also been proposed in order to improve propofol aqueous solubility.
Prodrugs of propofol have been reported (e.g., Gallop et al, WO2005/023204; Gibiansky et al., WO2007008869; Rogers et al., UA 76 802 C2; Wozniak et al., CA 2 548 216 Al).
Alkyl phosphate prodrugs of propofol e.g., Aquavan®, have been described in the literature (Baker et al., Anesthesiology 2005,103,860-876; Gibiansky et al., Anesthesiology 2005, 103,718- 729; Struys et al., Anesthesiology 2005, 103, 730-743; Schywalsky et al., Eur J Anaesthesiol 2003, 20, 182-190; Stella et al., International Publication No. WO200008033; Kumpulainen et al., Eur J Pharm Sci. 2008, 34(2-3): 110-7). Patent US6204257 (University of Kansas) discloses O-pho sphononoxymethy lpropo fo 1 derivatives .
Patent applications WO199958555 and WO2002013810 (Vyrex) disclose methods for treating or preventing migraine headaches using propofol prodrugs, such as mono(propofol)phosphate and
di(propofol)phosphate, that are much more soluble in water than propofol and that metabolize in vivo into the active propofol.
To date, propofol formulations are in injectable form due to the poor oral bioavailability of propofol. Injectable drug delivery systems are less conveninent than oral formulations due to several factors, particularly because they require assistance for administration, the painful application thereof, the extemporaneous preparation that such formulations usually require, or otherwise, the need for special storage at cool temperatures that readily prepared injectables demand.
There is a need in the art for improving propofol pharmacokinetics, in particular its oral bioavailability such that oral formulations are feasible.
It is an object of the present invention to provide derivatives and formulations of propofol that can be administered orally.
It is an object of the present invention to provide propofol derivatives and formulations that deliver the drug over a sustained period of time at concentrations efficacious for treatment of mammals including humans. Such propofol forms and formulations must be safe, i.e. having minimal side effects, and with appropriate pharmacokinetic profiles.
It is an object of the present invention to provide propofol derivatives and formulations that can improve one or more of the following pharmacokinetic parameters in respect of the currently available formulations: a longer half- life, increased volume of distribution, extended drug release, sustained plasma concentration, or a longer duration of action.
It is an object of the present invention to provide chemically stable derivatives of propofol. It is a further object of the present invention to provide chemically stable formulations of propofol. It is also an object of the present invention to provide soluble derivatives of propofol.
Summary of the invention
The present invention is based on the surprising finding that propofol can be derivatized, onto the phenolic group, with specific phosphonic moieties which show completely different solubility properties in certain pharmaceutically acceptable solvents, and improved oral bioavailability. Preferably the specific phosphonic moieties of the phosphonyl-containing propofol derivatives of this invention comprise a saturated acyclic, homocyclic or heterocyclic
group, or a combination thereof, attached to the phosphorus atom through a linker which may comprise one or more carbonyl or sulfonyl groups. The present invention provides oral formulations as well as injectable forms of propofol.
Description of the invention
As used herein, and unless otherwise stated, the term ' ' aryl ' ' designates any mono- or polycyclic aromatic monovalent hydrocarbon group having from 6 to 15 carbon atoms such as, but not limited to, phenyl, naphthyl, anthracenyl, phenanthracyl, fluoranthenyl, chrysenyl, pyrenyl, biphenyl, terphenyl, picenyl, indenyl, biphenyl, indacenyl, benzocyclobutenyl, benzocyclooctenyl and the like. Within this definition are also included groups wherein a phenyl ring is fused to a C4-S cycloalkyl group (the latter being as defined below) such as, for instance, indanyl, tetrahydronaphthyl, fluorenyl and the like. Within this definition are also included groups wherein a phenyl ring is fused to one or more saturated or unsaturated heterocyclic rings each containing at least one heteroatom selected from the group consisting of nitrogen, oxygen and sulfur such as, for instance, benzothienyl, thianthrenyl, chromenyl, xanthenyl, phenoxathiinyl, benzofuranyl, isobenzofuranyl, indolyl, isoindolyl, indazolyl, quinolyl, isoquinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, cinnolinyl, carbazolyl, carbolinyl, acridinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, chromanyl, isochromanyl, phenoxazinyl, phenothiazinyl, isoindolinyl, benzoisoquinolinyl and the like. Each of said aryl groups may be optionally substituted, in particular at the ortho, meta and/or para positions of the phenyl ring, with one or more substituents independently selected from the group consisting of chloro, bromo, iodo, trifluoromethyl, trifluoromethoxy, Ci_6 alkyl and Ci_6 alkoxy (the latter being as defined below) such as for instance bromochlorophenyl, bromotolyl, chlorotolyl, iodotolyl, dibromophenyl, dichlorophenyl, diiodophenyl, dimethoxyphenyl, dimethylphenyl (xylyl), diisopropylphenyl, 2,4,6-trimethylphenyl (mesityl), trimethoxyphenyl and the like.
As used herein with respect to a substituent, and unless otherwise stated, the term "Ci_4 alkyl" refers to a straight or branched chain saturated acyclic hydrocarbon monovalent group having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, n-butyl, 1-methylethyl (isopropyl), 2-methylpropyl (isobutyl) and 1,1-dimethylethyl (tert-butyϊ).
As used herein with respect to a substituent, and unless otherwise stated, the term "Ci_6 alkyl" refers to straight and branched chain saturated acyclic hydrocarbon monovalent groups having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, n-butyl, 1-methylethyl (isopropyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), 2-methyl-butyl, n-pentyl, dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, and the like. The terms "C1-10 alkyl"
and "Ci_2o alkyl" similarly refer to straight and branched chain saturated acyclic hydrocarbon monovalent groups having from 1 to 10 and from 1 to 20 carbon atoms, respectively, thus including those already listed for Ci_6 alkyl and the like, as well as n-octyl, n-nonyl, n-decyl, for "Ci_io alkyl", and n-undecyl, n-dodecyl, n-tetradecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n- pentadecyl, n-nonadecyl and 1-eicosanyl for "Ci_2o alkyl".
As used herein, and unless otherwise stated, the term "Ci_6alkoxy" refers to substituents wherein a carbon atom of a Ci_6 alkyl group (such as defined herein), is attached to an oxygen atom through a single bond such as, but not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy, isopropoxy, sec-butoxy, tert-butoxy and isopentoxy.
As used herein with respect to a substituent, and unless otherwise stated, the term "C3_ i2cycloalkyl" means a mono- or polycyclic saturated hydrocarbon monovalent radical having from 3 to 12 carbon atoms, such as for instance cyclopropyl, eye Io butyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cycloundecyl, cyclododecyl and the like, or a C7-Io polycyclic saturated hydrocarbon monovalent radical having from 7 to 10 carbon atoms such as, for instance, norbornyl, fenchyl, trimethyltricycloheptyl or adamantyl.
As used herein with respect to a substituent, and unless otherwise stated, the term "saturated heterocyclyl" refers to a mono- or polycyclic, saturated monovalent hydrocarbon group having from 2 up to 15 carbon atoms and including one or more heteroatoms in one or more heterocyclic rings, each of said rings having from 3 to 10 atoms (and optionally further including one or more heteroatoms attached to one or more carbon atoms of said ring, for instance in the form of a carbonyl or thiocarbonyl or selenocarbonyl group, and/or to one or more heteroatoms of said ring, for instance in the form of a sulfone, sulfoxide, N-oxide, phosphate, phosphonate or selenium oxide group), each of said heteroatoms being independently selected from the group consisting of nitrogen, oxygen, sulfur, selenium and phosphorus; representative but non-limiting examples within this group are 1,2-oxathiolanyl, oxiranyl, aziridinyl, imidazolidinyl, pyrazolidinyl, pyrrolidinyl, piperidinyl, piperazinyl, quinuclidinyl, morpholinyl, l,3-dioxa-4- cyclohexyl and the like.
As used herein with respect to a substituent, and unless otherwise stated, the term "halogen" refers to any one of fluoro, chloro, bromo and iodo.
According to a first aspect, the present invention relates to a class of phosphonyl-containing propofol derivatives represented by the structural formula (I):
and the salts and stereoisomers thereof, wherein:
- a single bond,
- p is an integer from 1 to 8,
- each R3 and each R4 is independently selected from the group consisting of Ci_2oalkyl, C3. 12alkyl, C3-i2cycloalkyl-Ci_4alkyl, saturated heterocyclyl and saturated heterocyclyl-Ci_ 4alkyl, and - X and Y are each independently C or S(O),
- Z is selected from the group consisting of O, S(O) and NR5,
- W is selected from the group consisting of halogen, OH, S(O)H and 0"M+ wherein M+ is a monovalent cation (such as, but not limited to, an alkali metal cation, e.g. Na+ or K+); and
- R5 is selected from the group consisting of hydrogen and C1-10 alkyl.
Within this class, a useful embodiment is a phosphonyl-containing phenolic derivative represented by the structural formula (I) wherein R3 and R4 are independently -(CH2)n-CH3 wherein n is an integer from 8 to 16.
Specifically useful embodiments of this first aspect of the present invention include, but are not limited to, these wherein:
a single bond,
- p is an integer from 2 to 3;
- each R3 and each R4 is independently selected from the group consisting of Ci_2oalkyl and C3. 12alkyl;
- X and Y are each independently C;
- Z is O;
- W is selected from the group consisting of halogen and OH.
Several specific embodiments as described herein-above may be combined independently together, especially with respect to the choice of L, p, R3, and R4.
It should be noted that the radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable. When any variable occurs more than one time in any moiety, each definition is independent. Radicals used in the definitions of the variables include all possible isomers unless otherwise indicated. For instance pentyl includes 1 -pentyl, 2-pentyl and 3 -pentyl.
Whenever used hereinafter, the term "compounds of formula (I)", or "the present compounds" or similar terms, it is meant to include the compounds of formula (I), the salts thereof; and the stereo chemically isomeric forms thereof.
The compounds of formula (I) may have several centers of chirality, particularlyin respect to the L group when branched, and exist as stereochemically isomeric forms. The term "stereochemically isomeric forms" as used herein defines all the possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess. With reference to the instances where (R) or (S) is used to designate the absolute configuration of a chiral atom within a substituent, the designation is done taking into consideration the whole compound and not the substituent in isolation.
Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereo chemically isomeric forms, which said compound might possess. Said mixture may contain all diastereomers and enantiomers of the basic molecular structure of said compound. All stereo chemically isomeric forms of the compounds of the present invention both in pure form or mixed with each other are intended to be embraced within the scope of the present invention.
Pure stereoisomeric forms of the compounds and intermediates as mentioned herein are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates. In particular, the term
"stereoisomerically pure" concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i.e. minimum 80% of one isomer and maximum 20% of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to 100% and most in particular having a stereoisomeric excess of 97% up to 100%. The terms "enantiomerically pure" and "diastereomerically pure" should be understood in a similar way, but then having regard to the enantiomeric excess, and the diastereomeric excess, respectively, of the mixture in question.
Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures. For instance, enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphorsulfonic acid. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occur stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereospecifϊc methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
The diastereomeric racemates of the compounds of formula (I) can be obtained separately by conventional methods. Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.
The present invention is also intended to include all isotopes of atoms occurring on the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-B and C-14.
For therapeutic use, salts of the compounds of formula (I) are those wherein the counter-ion is pharmaceutically acceptable, which salts can be referred to as pharmaceutically acceptable acid and base addition salts. However, salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound. All salts, whether pharmaceutically acceptable or not, are included within the ambit of the present invention.
The pharmaceutically acceptable acid and base addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid and base addition salt forms that the compounds of formula (I) are able to form. The pharmaceutically acceptable acid addition salts can conveniently be obtained by treating the base form with such appropriate acid in an anion form. Appropriate anions comprise, for example, acetate, benzenesulfonate , benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsyiate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate (embonate), pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, triethiodide, and the like. Conversely said salt forms can be converted by treatment with an appropriate base into the free base form.
The compounds of formula (I) containing an acidic proton may also be converted into their nontoxic metal or amine addition salt forms by treatment with appropriate organic and inorganic bases in a cation form. Appropriate basic salts comprise those formed with organic cations such as benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, and the like; and those formed with metallic cations such as aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, and the like. Conversely said salt forms can be converted by treatment with an appropriate acid into the free form.
Some of the compounds of formula (I) may also exist in their tautomeric form. Such forms, although not explicitly indicated in the above formula, are intended to be included within the scope of the present invention.
According to another aspect, the present invention relates to various methods for making the phosphonyl-containing propofol derivatives defined in any one of the above embodiments, in particular wherein the linker L may have any one of the above meanings. These methods usually proceed in at least two steps.
According to a first method of the present invention, phosphonyl-containing propofol derivatives represented by the structural formula (I) wherein L is a single bond can be made according to the following sequence of steps:
- reacting propofol with a phosphorus oxyhalide (e.g. phosphorus oxychloride or phosphorus oxybromide) preferably in the presence of a catalytic amount of a tertiary amine such as, but not limited to, triethylamine, to produce a phosphorus oxyhalide intermediate with the structural formula (II), wherein Q is a halogen, preferably chloro or bromo; and
(H) reacting the phosphorus oxyhalide intermediate (II) with a saturated acyclic, homocyclic or heterocyclic mono-alcohol R3OH wherein R3 is preferably selected from the group consisting of Ci_2oalkyl, C3_i2cycloalkyl, C3_i2cycloalkyl-Ci_4alkyl, saturated heterocyclyl and saturated heterocyclyl-Ci_4 alkyl, in particular R3 may be -(CH2)n-CH3 wherein n is an integer preferably from 8 to 16.
An illustrative embodiment of the first production method of the present invention, wherein L is a single bond and R3 is a dodecyl group, is schematically shown in figure 1.
Suitable mono-alcohols R3OH for use in the first production methods of the present invention include, but are not limited to:
- acyclic, linear or branched, mono-alcohols such as, but not limited to, methanol, ethanol, n- propanol, n-butanol, n-pentanol, n-hexanol, n-heptanol, 2,2-dimethyl-3-pentanol, 2,3- dimethyl-3-pentanol, 2,4-dimethyl-3-pentanol, 4,4-dimethyl-2-pentanol, n-octanol, n- nonanol, n-decanol, n-decanol, n-undecanol, n-dodecanol, n-tridecanol, n-tetradecanol, n- pentadecanol, n-hexadecanol, n-heptadecanol, and n-octadecanol;
- homocyclic mono-alcohols such as, but not limited to, cyclobutanol, cyclopentanol, 1- methylcyclopentanol, 2-methylcyclopentanol, 3-methyl-cyclopentanol, cyclohexanol, 1- methylcyclohexanol, 2-methylcyclohexanol, 3-methylcyclohexanol, 4-methylcyclohexanol, 2-te/t-butylcyclohexanol, 4-te/t-butylcyclohexanol, 1-adamantanol, 2-adamantanol, 1,3,3- trimethyl-2-norbornanol, cycloheptanol, cyclooctanol, and cyclododecanol;
- mixed acyclic-homocyclic mono-alcohols such as, but not limited to, cyclopropanemethanol, cyclobutanemethanol, cyclopentanemethanol, cyclohexylmethanol, 2-cyclohexylethanol, 3-cyclohexyl- 1 -propanol, 3-cyclopentyl- 1 -propanol, cycloundecanemethanol, 2-norbornanemethanol, 1-adamanemethanol, 1-adamaneethanol, cycloheptanemethanol, and cyclododecanemethanol;
- saturated heterocyclyl mono-alcohols such as, but not limited to, 4-hydroxypiperidine, 3- hydroxypiperidine, 3 -hydroxy- 1-methylpiperidine, 4-hydroxy-l-methylpiperidine, 1-methyl- 3-pyrrolidinol, tetrahydro-4H-pyran-4-ol and 3-quinuclidinol ;
- mixed acyclic-saturated heterocyclic mono-alcohols such as, but not limited to, l-(2- hydro xyethyl)piperazine, 4-(2-hydroxyethyl)morpholine, l-(2-hydroxyethyl)pyrrolidine, 1- methyl-2-pyrrolidineethanol, (S)- 1 -methyl-2-pyrrolidinemethanol, (2- hydroxyethyl)piperidine, (hydro xymethyl)-piperidine, tetrahydropyran-2-methano 1, tetrahydro-3-furanmethanol, tetrahydrofurfuryl alcohol, dihydro-5-(hydroxymethyl)-2(3H)- furanone and 1-aziridineethanol.
According to a second method of the present invention, phosphonyl-containing propofol derivatives represented by the structural formula (I), wherein L is -(CΗ2)P-O-X(O)-, X is C or S(O) and p is an integer from 1 to 8, can be made according to the following sequence of steps:
- reacting a carbonyl chloride R3COCl or sulfonyl chloride R3SO2Cl (wherein R3 is preferably selected from the group consisting of Ci_2oalkyl, C3-12CVC Io alkyl, C3-i2cycloalkyl-Ci_4alkyl, saturated heterocyclyl and saturated heterocyclyl-Ci_4alkyl, in particular R3 may be -(CH2)n-CH3 wherein n is an integer preferably from 8 to 16), with a linear acyclic diol represented by the structural formula HO-(CH2)P-OH wherein p is an integer from 1 to 8, to form an intermediate represented by the structural formula R3X(O)O-(CH2)P-OH; and - this intermediate R X(0)0-(CH2)p-0H is then reacted with a phosphorus oxyhalide intermediate with the structural formula (II) (wherein Q is a halogen, preferably chloro or
bromo), itself obtainable in the same way as in the first step of the first production method of the present invention described above, to form a phosphonyl-containing propofol derivative wherein W is a halogen; this reaction preferably takes place in the presence of a catalytic amount of a tertiary amine such as, but not limited to, triethylamine, and in the presence of an organic solvent such as (but not limited to) toluene.
The second method of the present invention may further comprise a final step of transforming, e.g. through hydrolysis, the phosphonyl-containing propofol derivative wherein W is a halogen into the corresponding phosphonyl-containing propofol derivative wherein W is hydroxyl.
An illustrative embodiment of the second production method of the present invention, wherein R3 is an undecyl group, X is C and p is 2, is schematically shown in figure 2A (first step) and figure 2B (second step and hydrolysis step).
Suitable acyclic diols for use in the second production method of the present invention include, but are not limited to, ethylene glycol, 1,3-propanediol, 1,4-butanediol, 1,5-pentanediol, 2,4- dimethyl-2,4-pentanediol, 2,5-dimethyl-2,5-hexanediol, 1,6-hexanediol, and 1,8-octanediol.
Suitable carbonyl chlorides R3COCl for use in the second production method of the present invention include, but are not limited to, those wherein R3 is preferably selected from the group consisting of Ci_2oalkyl, C3_i2cycloalkyl, C3_i2cycloalkyl-Ci_4alkyl, saturated heterocyclyl and saturated heterocyclyl-C^alkyl, in particular R3 may be -(CH2)n-CH3 wherein n is an integer preferably from 8 to 16. Particularly suitable examples thereof include:
- acyclic, linear or branched, carbonyl chlorides including alkanoyl chlorides such as, but not limited to, acetyl chloride, propionyl chloride, butyryl chloride, isobutyryl chloride, valeryl chloride, isovaleryl chloride, pivaloyl chloride, capryloyl chloride, nonanoyl chloride, decanoyl chloride, lauroyl chloride, myristoyl chloride, palmitoyl chloride, stearoyl chloride and the like;
- homocyclic carbonyl chlorides including cycloalkanoyl chlorides such as, but not limited to, cyclobutanecarbonyl chloride, cyclopentanecarbonyl chloride, cyclohexanecarbonyl chloride,
1 -methyl- 1 -eye Io hexanecarbonyl chloride, 2 -methyl- 1 -cyclohexanecarbonyl chloride, 3- methyl-1 -cyclohexanecarbonyl chloride, 4-methyl-l-cyclo-hexanecarbonyl chloride, cycloheptanecarbonyl chloride, 1-adamantanecarbonyl chloride and the like;
- mixed acyclic-homocyclic carbonyl chlorides including cycloalkyl-alkanoyl chlorides such as, but not limited to, cyclohexylacetyl chloride, cyclopentylacetyl chloride, 2- norbornaneacetyl chloride, 1-adamantane-carbonyl chloride and the like;
- saturated heterocyclyl carbonyl chlorides such as, but not limited to, 4-morpholinylcarbonyl chloride, 1-pyrrolidinecarbonyl chloride, tetrahydro-2-furancarbonyl chloride and the like; and
- mixed acyclic-heterocyclic carbonyl chlorides including saturated heterocyclyl-alkanoyl chlorides such as, but not limited to, 3-(l,3-dioxan-2-yl)-propionyl chloride and 3-(l,3- dioxan-2-yl)-2-methylpropionyl chloride.
Suitable sulfonyl chlorides R3SO2Cl for use in the second production method of the present invention include, but are not limited to, the following: - acyclic, linear or branched, sulfonyl chlorides including alkanesulfonyl chlorides such as, but not limited to, methanesulfonyl chloride, ethanesulfonyl chloride, 1-propanesulfonyl chloride, 1-butanesulfonyl chloride, 1-hexanesulfonyl chloride, 1-octanesulfonyl chloride, 1- decanesulfonyl chloride and the like;
- homocyclic sulfonyl chlorides including cycloalkanesulfonyl chlorides such as, but not limited to, cyclopentanesulfonyl chloride, cyclohexanesulfonyl chloride and the like;
- saturated heterocyclyl sulfonyl chlorides such as, but not limited to, 4-morpholinesulfonyl chloride, pyrrolidine- 1 -sulfonyl chloride and the like.
According to a third method of the present invention, phosphonyl-containing propofol derivatives represented by the structural formula (I), wherein L is -(CH2)P-O- and p is an integer from 1 to 8, can be made according to the following sequence of steps:
- reacting a saturated acyclic, homocyclic or heterocyclic mono-alcohol R3OH wherein R3 is preferably selected from the group consisting of Ci_2oalkyl, C3_i2cycloalkyl, C3_i2cycloalkyl- Ci_4alkyl, saturated heterocyclyl and saturated heterocyclyl-Ci_4 alkyl, in particular R3 may be -(CH2)n-CH3 wherein n is an integer preferably from 8 to 16, with an ω-halo (preferably ω-bromo) α-alcohol represented by the structural formula Q-(CH2)P-OH wherein p is an integer from 1 to 8 and Q is a halogen (preferably bromo); this reaction may take place in the presence of sodium hydride and a suitable solvent such as (but not limited to) tetrahydrofuran and results into a substituted alcohol intermediate represented by the structural formula R3O-(CH2)p-OH;
- this substituted alcohol intermediate represented by the structural formula R O-(CH2)P-OH is then reacted with a phosphorus oxyhalide intermediate with the structural formula (II)
(wherein Q is a halogen, preferably chloro or bromo), itself obtainable in the same way as in the first step of the first production method of the present invention described above, to form a phosphonyl-containing propofol derivative wherein W is a halogen; this reaction preferably takes place in the presence of a catalytic amount of a tertiary amine such as, but not limited to, triethylamine, and in the presence of an organic solvent such as (but not limited to) toluene.
The third method of the present invention may further comprise a final step of transforming, e.g. through hydrolysis, the phosphonyl-containing propofol derivative wherein W is a halogen into the corresponding phosphonyl-containing propofol derivative wherein W is hydroxyl.
An illustrative embodiment of the third production method of the present invention, wherein R is a linear alkyl group -(CH2)n-CH3, and p is 3, is schematically shown in figure 3 A (first step) and figure 3 B (second step and hydrolysis step).
Suitable mono-alcohols R3OH for use in the third production method of the present invention are the same as previously detailed with respect to the first production method of the present invention.
Suitable an ω-halo-α-alcohols for use in the third production method of the present invention include, but are not limited to, 2-bromoethanol (p = 2), 3-bromopropan-l-ol (p = 3), A- bromobutan-1-ol (p = 4), 5-bromopentan-l-ol (p = 5), 6-bromohexan-l-ol (p = 6), 7- bromoheptan-1-ol (p = 7), 8-bromooctan-l-ol (p = 8), and isomers thereof. For reactivity and yield optimisation purposes, ω-bromo alcohols are preferred. The type of alkyl group present in said alcohols is not important but may be limited in practice by commercial availability.
According to a fourth method of the present invention, phosphonyl-containing propofol derivatives represented by the structural formula (I), wherein:
R4 is selected from the group consisting of Ci_2oalkyl, C3-i2alkyl, C3-i2cycloalkyl-Ci_4 alkyl, saturated heterocyclyl and saturated heterocyclyl-Ci_4 alkyl, and
X or Y are each independently C or S(O), can be made according to the following sequence of steps: reacting 1,2,3-propanetriol is reacted with one or more carbonyl chlorides R'COCl and/or sulfonyl chlorides R5SO2Cl (wherein R' is defined in the same meaning as R3 and R4) to form a R3,R4-containing l,3-di(acyloxy)-propan-2-ol and/or a R3,R4-containing l,3-di(sulfoxy)- propan-2-ol intermediate; and reacting the latter l,3-di(acyloxy)-propan-2-ol or l,3-di(sulfoxy)-propan-2-ol intermediate, with a phosphorus oxyhalide intermediate with the structural formula (II) wherein Q is a halogen (preferably chloro or bromo),
(H) itself obtainable in the same way as in the first step of the first production method of the present invention described above, to form a phosphonyl-containing propofol derivative represented by the structural formula (I), wherein W is a halogen; this reaction preferably takes place in the presence of a catalytic amount of a tertiary amine such as, but not limited to, triethylamine, and in the presence of an organic solvent such as (but not limited to) toluene.
The fourth method of the present invention may further comprise a final step of hydro lysing the phosphonyl-containing propofol derivative wherein W is a halogen into the corresponding phosphonyl-containing propofol derivative, wherein W is hydroxyl.
According to the first step of this fourth method of this invention it is preferable, although this is not a required feature, that one single carbonyl chloride or sulfonyl chloride is used, thus introducing the same R3-containing and R4-containing moieties into the molecule (i.e. R3 = R4 and X = Y). Using two or more carbonyl chlorides and/or sulfonyl chlorides in this first step will usually result into the production of a complex mixture of intermediates, itself resulting after the second step into a complex mixture of phosphonyl-containing propofol derivatives represented by the structural formula (I), which may be difficult to separate into pure distinct entities. Alternatively, it may be possible to introducing different R3-containing and R4-containing moieties into the molecule (i.e. R3 differs from R4 and/or X differs from Y) by dividing the first step into two successive sub-steps wherein the R3-containing moiety and the R4-containing moiety are introduced in each sub-step, respectively, by adding different carbonyl chlorides and/or sulfonyl chlorides. This alternative method may however require that a hydroxyl group of 1,2,3-propanetriol is first protected by a conventional hydro xy-protecting group before performance of the first sub-step and then deprotected before performance of the second sub-step to avoid the formation of undesirable by-products. Upon observing this precaution, both R3 and R4, and both X and Y may independently be selected at will in the structural formula (I), depending upon the easiness of each sub-step and the desirable physical characteristics of the propofol derivative to be produced.
Suitable carbonyl chlorides R3COCl and R4COCl, and suitable sulfonyl chlorides R3SO2Cl and R4SO2Cl for use in the fourth method of this invention are the same as previously detailed with respect to the second production method of the present invention.
An illustrative embodiment of the fourth production method of the present invention, wherein R3 and R > 4 are both tridecyl groups and X and Y are both C, is schematically shown in figure 4 A (first step) and figure 4B (second step and hydrolysis step).
When a phosphonyl-containing propofol derivative of this invention, wherein W is hydroxyl, has been obtained e.g. according to any one of the four above-described methods, this derivative can be converted into a monovalent salt, i.e. a corresponding derivative wherein W is 0"M+ wherein M+ is a monovalent cation (such as, but not limited to, an alkali metal cation, e.g. Na+ or K+), by using techniques well known to the skilled person.
The type of reaction conditions, e.g. temperature, reaction time, molar ratio between the reactants, solvent of choice and the like, and the type of extraction and/or purification methods generally suitable for each synthetic step in any of the four above described production methods
of the present invention are well known to the skilled person. If necessary for optimisation of the reaction yield, a reaction step may be performed in the presence of an effective amount of a catalyst well known to the skilled person.
The resulting compounds may be optionally converted into a pharmaceutically acceptable salt or vice versa according to the methods known by the skilled in the art.
Further, compounds of formula (I) may be converted into each other following art-known functional group transformation reactions. For example, amino groups may be N-alkylated, nitro groups reduced to amino groups, a halo atom may be exchanged for another halo.
Pure stereo chemically isomeric forms of the compounds of formula (I) may be obtained by the application of art-known procedures. Diastereomers may be separated by physical methods such as selective crystallization and chromatographic techniques, e.g., counter-current distribution, liquid chromatography and the like.
The compounds of formula (I) may be obtained as racemic mixtures of enantiomers, which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) that are sufficiently basic or acidic may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid, respectively chiral base. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali or acid. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography, in particular liquid chromatography using a chiral stationary phase. Said pure stereochemical^ isomeric forms may also be derived from the corresponding pure stereo chemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifϊcally. Preferably if a specific stereoisomer is desired, said compound may be synthesized by stereospecific methods of preparation. These methods may advantageously employ enantiomerically pure starting materials.
In another aspect the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a propofol derivative according to any of the above-referred embodiments, and one or more pharmaceutically acceptable excipients.
The pharmaceutical compositions according to this invention may be administered orally or in any other suitable fashion. In case of oral administration, the preparation may have the form of a
tablet, aqueous dispersion, dispersable powder or granule, emulsion, hard or soft capsule, syrup, elixir or gel. The dosing forms may be prepared using any method known in the art for manufacturing these pharmaceutical compositions and may comprise as additives sweeteners, flavoring agents, coloring agents, preservatives and the like. Carrier materials and excipients are detailed hereinbelow and may include, inter alia, calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, binding agents and the like. The pharmaceutical composition of this invention may be included in a gelatin capsule mixed with any inert solid diluent or carrier material, or has the form of a soft gelatin capsule, in which the ingredient is mixed with a water or oil medium. Aqueous dispersions may comprise the biologically active composition or combined preparation in combination with a suspending agent, dispersing agent or wetting agent. Oil dispersions may comprise suspending agents such as a vegetable oil. Rectal administration is also applicable, for instance in the form of suppositories or gels.
Due to the significantly modified physico-chemical properties of the propofol derivatives of the present invention allowing their inclusion into complex types of pharmaceutical formulations such as, but not limited to, microemulsions, microsuspensions and nanosuspensions, injection (e.g. intramuscularly or intraperiteneously) is also applicable as a mode of administration, for instance in the form of injectable aqueous solutions or dispersions, depending upon the disorder to be treated and the condition of the patient. Examples of aqueous solutions include, for example, water, saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions and the like. The pharmaceutical injectable compositions may contain one or more pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions or to improve stability, appearance or ease of administration, such as buffering agents, tonicity adjusting agents, wetting agents, detergents and the like. Additives can also include additional active ingredients such as bactericidal agents, or stabilising agents. For example, the aqueous solution of the invention may contain one or more additives selected from the group consisting of sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate and triethanolamine oleate. These aqueous compositions can be sterilised by conventional, well-known sterilisation techniques, or can be sterile filtered. The resulting aqueous solutions can be packaged for use as such, or can be lyophilised, the lyophilised preparation being combined with a sterile aqueous solution prior to administration. Such aqueous solutions are appropriate for injection and, in particular, for intravenous injection. Intravenous injection is a particularly appropriate means of delivery for using a propofol derivative of this invention as an anti-migraine agent. The intravenous solution can include detergents and emulsifiers such as lipids. Aqueous solutions also are useful for oral and enteral
and other routes of administration as tonics, and for administration to mucous or other membranes as, e.g., nose or eye drops. The aqueous composition of this invention may contain the phenol derivative in an amount from about 1 mg/ml to about 100 mg/ml, preferably from about 5 to 20 mg/ml. Suitable dosages of the pharmaceutical compositions of the present invention, in particular injectable formulations, may range from 0.05 to 100 mg/Kg.
In one embodiment, the pharmaceutical composition of the present invention is in the form of an injectable. In another embodiment, the injectable is administered intravenously, intramuscularly, subcutaneously, intraperitoneally, intra-articularly, intralesionally, intraventricular^, by spinal injection, by intraosseous infusion, or transdermally.
The term "pharmaceutically acceptable carrier or excipient" as used herein in relation to any type of pharmaceutical compositions means any material or substance with which the active principle, i.e. the propofol derivative of this invention, may be formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and/or to facilitate its storage, transport or handling without impairing its effectiveness. The pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e. the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, pellets or powders.
Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art. There is no particular restriction to their selection within the present invention although special attention may be paid to the selection of suitable carrier combinations that can assist in properly formulating the propofol derivative in view of the expected time release profile. Suitable pharmaceutical carriers include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying or surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals.
The pharmaceutical compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, dissolving, spray-drying, coating and/or grinding the active ingredients, in a one-step or a multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface-active agents. The
compositions may also be prepared by micronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 μm, namely for the manufacture of microcapsules for controlled or sustained release of the biologically active agent.
Suitable surface-active agents to be used in the pharmaceutical compositions of the present invention are non-ionic, cationic and/or anionic surfactants having good emulsifying, dispersing and/or wetting properties. Suitable anionic surfactants include both water-soluble soaps and water-soluble synthetic surface-active agents. Suitable soaps are alkaline or alkaline-earth metal salts, unsubstituted or substituted ammonium salts of higher fatty acids (C10-C22), e.g. the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures obtainable form coconut oil or tallow oil. Synthetic surfactants include sodium or calcium salts of polyacrylic acids; fatty sulphonates and sulphates; sulphonated benzimidazole derivatives and alkylarylsulphonates. Fatty sulphonates or sulphates are usually in the form of alkaline or alkaline-earth metal salts, unsubstituted ammonium salts or ammonium salts substituted with an alkyl or acyl radical having from 8 to 22 carbon atoms, e.g. the sodium or calcium salt of lignosulphonic acid or dodecylsulphonic acid or a mixture of fatty alcohol sulphates obtained from natural fatty acids, alkaline or alkaline-earth metal salts of sulphuric or sulphonic acid esters (such as sodium lauryl sulphate) and sulphonic acids of fatty alcohol/ethylene oxide adducts. Suitable sulphonated benzimidazole derivatives preferably contain 8 to 22 carbon atoms. Examples of alkylarylsulphonates are the sodium, calcium or alcanolamine salts of dodecylbenzene sulphonic acid or dibutyl-naphthalenesulphonic acid or a naphtalene-sulphonic acid/formaldehyde condensation product. Also suitable are the corresponding phosphates, e.g. salts of phosphoric acid ester and an adduct of p-nonylphenol with ethylene and/or propylene oxide, or phospholipids. Suitable phospholipids for this purpose are the natural (originating from animal or plant cells) or synthetic phospholipids of the cephalin or lecithin type such as e.g. phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerine, lysolecithin, cardiolipin, dioctanyl-phosphatidylcholine, dipalmitoylphoshatidylcholine and their mixtures.
Suitable non-ionic surfactants include polyethoxylated and polypropoxylated derivatives of alkylphenols, fatty alcohols, fatty acids, aliphatic amines or amides containing at least 12 carbon atoms in the molecule, alkylarenesulphonates and dialkylsulphosuccinates, such as polyglycol ether derivatives of aliphatic and cycloaliphatic alcohols, saturated and unsaturated fatty acids and alkylphenols, said derivatives preferably containing 3 to 10 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenol. Further suitable non-ionic surfactants are water-soluble adducts of polyethylene oxide with poylypropylene glycol, ethylenediamino -polypropylene glycol
containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethyleneglycol ether groups and/or 10 to 100 propyleneglycol ether groups. Such compounds usually contain from 1 to 5 ethyleneglycol units per propyleneglycol unit. Representative examples of non-ionic surfactants are nonylphenol-polyethoxyethanol, castor oil poly-glycolic ethers, polypropylene/polyethylene oxide adducts, tributylphenoxy-polyethoxyethanol, polyethyleneglycol and octylphenoxypolyethoxyethanol. Fatty acid esters of polyethylene sorbitan (such as polyoxyethylene sorbitan trioleate), glycerol, sorbitan, sucrose and pentaerythritol are also suitable non-ionic surfactants.
Suitable cationic surfactants include quaternary ammonium salts, preferably halides, having four hydrocarbon radicals optionally substituted with halo, phenyl, substituted phenyl or hydroxy; for instance quaternary ammonium salts containing as N-substituent(s) at least one Cs-C22 alkyl radical (e.g. cetyl, lauryl, palmityl, myristyl, oleyl and the like) and, as further substituents, unsubstituted or halogenated lower alkyl, benzyl and/or hydroxy-Ci_4 alkyl radicals.
A more detailed description of surface-active agents suitable for this purpose may be found for instance in «McCutcheon's Detergents and Emulsifiers Annual» (MC Publishing Crop., Ridgewood, New Jersey, 1981), «Tensid-Taschenbuch», 2nd ed. (Hanser Verlag, Vienna, 1981) and «Encyclopaedia of Surfactants)) (Chemical Publishing Co., New York, 1981).
Structure-forming, thickening or gel- forming agents may be included into the pharmaceutical compositions and combined preparations of the invention. Suitable such agents are in particular highly dispersed silicic acid, such as the product commercially available under the trade name Aerosil; bentonites; tetraalkyl ammonium salts of montmorillonites (e.g. products commercially available under the trade name Bentone), wherein each of the alkyl groups may contain from 1 to 20 carbon atoms; cetostearyl alcohol and modified castor oil products (e.g. the product commercially available under the trade name Antisettle).
Gelling agents which may be included into the pharmaceutical compositions of the present invention include, but are not limited to, cellulose derivatives such as carboxymethylcellulose, cellulose acetate and the like; natural gums such as arabic gum, xanthum gum, tragacanth gum, guar gum and the like; gelatin; silicon dioxide; synthetic polymers such as carbomers, and mixtures thereof. Gelatin and modified celluloses represent a preferred class of gelling agents.
Other optional excipients which may be included in the pharmaceutical compositions of the present invention include additives such as magnesium oxide; azo dyes; organic and inorganic
pigments such as titanium dioxide; UV-absorbers; stabilisers; odor masking agents; viscosity enhancers; antioxidants such as, for example, ascorbyl palmitate, sodium bisulfite, sodium metabisulfite and the like, and mixtures thereof; preservatives such as, for example, potassium sorbate, sodium benzoate, sorbic acid, propyl gallate, benzylalcohol, methyl paraben, propyl paraben and the like; sequestering agents such as ethylene-diamine tetraacetic acid; flavoring agents such as natural vanillin; buffers such as citric acid and acetic acid; extenders or bulking agents such as silicates, diatomaceous earth, magnesium oxide or aluminum oxide; densification agents such as magnesium salts; and mixtures thereof.
Additional ingredients may be included in order to control the duration of action of the bio logically- active agent (phenol derivative) in the compositions of the invention. Control release compositions may thus be achieved by selecting appropriate polymer carriers such as for example polyesters, polyamino-acids, polyvinyl-pyrrolidone, ethylene-vinyl acetate copolymers, methylcellulose, carboxy-methylcellulose, protamine sulfate and the like. The rate of drug release and duration of action may also be controlled by incorporating the active agent into particles, e.g. microcapsules, of a polymeric substance such as hydrogels, polylactic acid, hydroxymethylcellulose, polymethylmethacrylate and the other above-described polymers. Such methods include colloid drug delivery systems like liposomes, microspheres, microemulsions, nanoparticles, nanocapsules and so on. Depending upon the route of administration, the pharmaceutical composition of this invention may also require protective coatings.
Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation thereof. Typical carriers for this purpose therefore include biocompatible aqueous buffers, ethanol, glycerol, propylene glycol, polyethylene glycol, complexing agents such as cyclodextrins and the like, and mixtures thereof in any suitable proportions.
Other modes of local drug administration can also be used. For example, the selected propofol derivative active agent may be administered topically, in an ointment, gel or the like, or transdermally, using a conventional transdermal drug delivery system.
The compounds of the present invention are useful because they possess pharmacological activity in animals, including humans. In particular, the compounds are useful as anesthetic, sedative-hypnotic, or as anti-migraine agent. For example, they are useful in inducing and maintaining general anesthesia, initiation and maintenance of Monitored Anesthesia Care (MAC) sedation, initiation and maintenance of Intensive Care Unit (ICU) sedation in intubated
mechanically ventilated subjects, combined sedation and regional anesthesia, cardiac anesthesia, neuroanesthesia. They can also be used in the treatment or prevention of migraine headache, for reducing post-operative nausea and vomiting, for providing anti-emetic activity, for treating refractory status epilepticus, or for use as an anti-convulsant in a mammal.
The compounds of the present invention, pharmaceutically acceptable salts thereof, or any subgroup thereof may therefore be used as a medicament. Said use as a medicament or method of treatment comprises the systemic administration to a subject in need thereof, of an amount effective to induce or maintain anesthesia, to treat or prevent migraine headache, to reduce post- operative nausea and vomiting, for providing anti-emetic activity, for treating refractory status epilepticus, or for use as an anti-convulsant in a mammal
The present invention also relates to the use of the present compounds, pharmaceutically acceptable salts thereof, or any subgroup thereof for the manufacture of a medicament for the induction or maintenance of anesthesia, for the treatment or prevention of migraine headache, to reduce post-operative nausea and vomiting, for providing anti-emetic activity, for treating refractory status epilepticus, or for use as an anti-convulsant in a mammal. In other words, the present invention further relates to the compound of formula (I), pharmaceutically acceptable salts thereof, or any subgroup thereof, for use as an anesthetic agent, sedative-hypnotic, or as anti-migraine agent. Also, the present invention relates to a a method of induction or maintenance of anesthesia, which comprises administering an effective amount of a compound according to any one of the embodiments herein, to a patient in need of such induction or maintenance.
In addition, the present invention relates to a method of extending the release of propofol, which comprises converting propofol into a compound of formula (I), a pharmaceutically acceptable salt thereof, or any subgroup thereof.
The following examples are merely illustrative of some non- limiting embodiments of the present invention.
Examples
This example illustrates the production of propofol derivatives of the present invention being represented by the structural formula (I) wherein L is a single bond and R3 is a dodecyl group, as schematically shown in Figure 1 and following the principles of the first production method of the present invention, as outlined herein-above.
In this way, 2,6-diisopropylphenyl dodecyl hydrogen phosphate was obtained with a 60% yield, and was characterised by proton nuclear magnetic resonance and mass spectrometry as follows:
1H NMR (500 MHz, CDCl3): peaks δ at 7.05-7.02 (m), 3.79-3.61 (m), 3.59-3.54 (m), 1.42-1.15 (m), 1.14 (d, J=6.5 Hz), and 0.88 (t, J=7 Hz) ppm; and
EMI-MS m/z: 425 [M-I]"
Example 2 - Production of propofol phosphonyl derivatives wherein L is
-(CHz)2-O-C(O)- Figure 2 A
OH CH2Ci2
C-j 1H23COQ -. OH
HO " \-UM » -*■ C11H23COO rt, overnight ] 1 ^
Figure 2B
This example illustrates the production of propofol derivatives of the present invention being represented by the structural formula (I) wherein L is -(CH2)2-O-C(O)- and R3 is a undecyl group, as schematically shown in figures 2A and 2B, and following the principles of the second production method of the present invention, as outlined herein-above. In this way the final compound was obtained, after hydrolysis, with a 45% yield, and was characterised by proton nuclear magnetic resonance and mass spectrometry as follows:
1H NMR (500 MHz, CDCl3): peaks δ at 7.06 (bs), 4.03 (bs), 3.93 (bs), 3.51 (bs), 2.20- 2.17 (m), 1.53 (s), 1.25 (s), 1.14 (d, J=7 Hz), and 0.88 (t, J= 7 Hz) ppm; and
ESI-MS nVz: 483.2 [M]"
Example 3 - Production of propofol phosphonyl derivatives wherein L is -(CH2)3-O-
This example illustrates the production of propofol derivatives of the present invention being represented by the structural formula (I) wherein L is -(CH2)S-O- and R3 is a dodecyl group, as schematically shown in figures 3 A and 3B and following the principles of the third production method of the present invention, as outlined herein-above.
In this way the final compound was obtained, after hydrolysis, with a 25% yield, and was characterised by proton nuclear magnetic resonance and mass spectrometry as follows:
1H NMR (500 MHz, DMSO.d6): peaks δ at 6.99-6.93 (m), 3.83 (bs), 3.71-3.69 (m), 3.34 (m), 1.70 (bs), 1.44 (bs), 1.23-1.10 (m), 1.12 (d, J = 6.5Hz), and 0.84 (t, J = 7) ppm; and
MS nVz: 485 [M + I]+
Example 4 - Production of propofol phosphonyl derivatives
Figure 4A
*">
C13H27COOH + SOCi; C^Hg^CGCI rt( overnight CH2Ci2
C13H27COCI + HO ^OH C13H27COO' ' 0OC13H27 rt, overnight
OH OH
represented by the structural formula (I) wherein L is O s x and Y are a carbon atom, R3 and R4 are a tridecyl group each, as schematically shown in figures 4A and 4B and following the principles of the fourth production method of the present invention, as outlined herein-above.
In this way the final compound was obtained, after hydrolysis, with a 20% yield, and was characterised by proton nuclear magnetic resonance and mass spectrometry as follows: - 1H NMR (500 MHz, DMSO.d6): peaks δ at 6.98-6.91 (s), 4.51 (bs), 4.16-4.14 (m), 4.08-
4.05 (m), 3.72-3.70 (m), 2.27-2.24 (m), 1.50-1.48 (s), 1.22-1.07 (m), 1.12 (d, J= 7 Hz), and 0.75 (t, J= 7 Hz) ppm; and
EMS-MS m/z: 753 [M + I]+
Example 5 - Solubility of propofol derivatives in pharmaceutical solvents
Table 1 provides the solubility data at 25°C, expressed in mg/ml, of the final propofol derivatives produced and characterised in examples 1-4 respectively. The solubility determination method used was as follows: a suspension of 6 mg of the relevant propofol derivative in 500 μl of the relevant pharmaceutical solvent was rotatively shaken for 24 hours at 800 rpm at 25°C. The
saturated propofol derivative solution was filtered (0.45 μm) and 150 μl of the filtrate was diluted in dimethylsulfoxide (50 μl DMSO). This solution was assayed, each assay being carried out in three-fold, by measurement with Liquid Chromatography-Mass Spectrometry (LCMS, lμl and 10 μl injection). Standards were prepared by dissolving the relevant propofol derivative in DMSO (1 mg/ml). To determine the solubility, four aliquots (0.5, 1, 2, 4 μl) of the standard solution were injected using the same LCMS conditions as for the above exemplary samples.
Table 1
Example Ex. 1 Ex. 2 Ex. 4 Ex. 3
Pharmaceutical solvent
H2O (pH = 2) 24.4 0.8 4.8 1.7
H2O (pH = 7) 17.7 9.6 7.3 1.7
H2O (pH = 10) 2.1 2.4 10.0 2.4
H2O/hydroxypropyl-β-cyclodextrin (60/40) 5.1 2.7 0.0 1.4
H2O/Vitamin E TPGS (90/10) 16.3 7.5 15.6 1.9
H2O/Cremophor RH 40 a (80/20) 39.4 0.1 0.0 3.3
H2O/Polysorbate 80 (80/20) 16.3 29.0 0.0 1.8
Polyethylene glycol MW 400 34.5 12.1 13.0 2.3
Miglyol 812 b 28.1 7.7 0.0 4.3 a an emulsifying agent obtained by reacting 45 moles of ethylene oxide with 1 mole of hydrogenated castor oil, commercially available from BASF AG (Germany). b a caprylic/capric acid triglyceride, commercially available from SASOL GmbH (Germany).
Example 6 - Chemical stability of a propofol derivative wherein L is a single bond in pharmaceutical solvents Table 2 provides the chemical stability data in some pharmaceutical solvents, expressed as the weight percentage of the final propofol derivative produced and characterised in example 1 that remained in solution after a certain period of time. The test was carried out twice, and the remaining weight % was determined by Liquid Chromatography-Mass Spectrometry (LCMS).
Table 2
4 hours 1 day 2 days 7 days 14 days Pharmaceutical solvent H2O (pH = 2) 99. 6 100 .0 99 .5 99 .2 98. 9 H2O (pH = 7) 99. 1 98. 9 98 .9 97 .0 95. 0 H2O (pH = 10) 95. 8 95. 2 94 .8 93 .1 90. 9
H2O/hydroxypropyl-β-cyclodextrin (60/40) 99.9 97.3 96.9 96.6 95.6 Polyethylene glycol 400 99.8 99.6 99.4 99.0 98.7
Table 2 shows that at most 9% of the propofol derivative did not remain in the relevant aqueous or hydro xypropyl-β-cyclodextrin or polyethylene glycol solution after 14 days.
Example 7 - Chemical stability in pharmaceutical solvents of a propofol derivative wherein L is -(CHz)2-O-C(O)-
Table 3 provides the chemical stability data in some pharmaceutical solvents, expressed as the weight percentage of the final propofol derivative produced and characterised in example 2 that remained in solution after a certain period of time. The test was carried out twice, and the remaining weight % was determined by Liquid Chromatography-Mass Spectrometry (LCMS).
Table 3
4 hours 1 day 2 days 7 days 14 days
Pharmaceutical solvent
H2O (pH = 2) 99.6 98.5 98.1 97.2 97.1
H2O (pH = 7) 98.1 97.7 97.3 97.2 96.5
H2O (pH = 10) 99.2 99.4 98.8 98.8 98.4
H2O/hydro xypropyl-β-cyclodextrin (60/40) 98.6 98.9 98.6 98.3 97.7
Polyethylene glycol 400 99.6 99.8 98.9 98.8 99.9
Table 3 shows that at most 3.5% of the propofol derivative did not remain in the relevant aqueous or hydro xypropyl-β-cyclodextrin or poly-ethylene glycol solution after 14 days.
Example 8 - Chemical stability, in some pharmaceutical solvents, of a propofol derivative wherein L is -(CH2)3-O-
Table 4 provides the chemical stability data in some pharmaceutical solvents, expressed as the weight percentage of the final propofol derivative produced and characterised in example 3 that remained in solution after a certain period of time. The test was carried out twice, and the remaining weight % was determined by Liquid Chromatography-Mass Spectrometry (LCMS).
Table 4
4 hours 1 day 2 days 7 days 14 days Pharmaceutical solvent H2O (pH = 2) 98.7 97.9 98.2 96.8 96.2
H2O (pH = 7) 96.8 95.0 93.9 93, .5 92.6
H2O (pH = 10) 96. 9 96 .3 96. 3 95, .9 95 .0
H2θ/hydroxypropyl-β-cyclodextrin (60/40) 96. 9 95 .4 95. 0 94, .0 92 .0
Polyethylene glycol 400 98. 6 98 .0 97. 1 96, .0 95 .2
Table 4 shows that at most 8% of the propofol derivative did not remain in the relevant aqueous or hydro xypropyl-β-cyclodextrin or polyethylene glycol solution after 14 days.
Example 9 - Chemical stability of a propofol derivative prepared in Example 4 in pharmaceutical solvents
Table 5 provides the chemical stability data in some pharmaceutical solvents, expressed as the weight percentage of the final propofol derivative produced and characterised in example 4 that remained in solution after a certain period of time. The test was carried out twice, and the remaining weight % was determined by Liquid Chromatography-Mass Spectrometry (LCMS).
Table 5
4 hours 1 day 2 days 7 days 14 days
Pharmaceutical solvent
H2O (pH = 2) 98 .3 99. 3 97 .9 95 .4 95 .0
H2O (pH = 7) 96 .4 95. 5 94 .5 91 .7 88 .4
H2O (pH = 10) 98 .0 98. 8 97 .1 97 .5 97 .1
Polyethylene glycol 400 97 .2 97. 5 97 .1 97 .0 96 .8
Table 5 shows that at most 12% of the propofol derivative did not remain in the relevant aqueous or hydro xypropyl-β-cyclodextrin or polyethylene glycol solution after 14 days.
Example 10 - Pharmacokinetic profile characterization of the propofol derivatives prepared in Examples 1-4
The pharmacokinetic (PK) parameters of the propofol prodrugs prepared in Examples 1-4 were measured after a single oral dose (po) in male rats and the relative oral bioavailability was determined.
A total of 36 rats, randomly assigned to 12 treatment groups, were given a single oral dose of the propofol prodrugs prepared in Examples 1-4. The rats were fed a standard diet and fastened overnight prior to the administration of the test material. On the day of dosing ,food was provided approximately 4 hours following dosing.
Prodrugs were dissolved either in mygliol 812, PBS, 0.5% polysorbate 80, 10% vitamin E TPGS or PEG 400. The propofol prodrugs were provided separately, and each solution was prepared freshly just before the start of each experiment in a concentration ranging from eq 1.75 - 3.33 mg propofol/mL. An overview of the prodrug solutions is given in Table 6. All rats were dosed by oral gavage and the volume was calculated based on the rats body weight 10 minutes prior to administration. Furthermore, during the course of the experiment, the individual body weights of the rats were also recorded at regular time periods.
Blood samples were taken preferably from the tail vein from each rat 5 minutes before the start of dosing (= predose) and, 10 min, 20 min, 30 min, Ih, 2h, 3h, 4h, 5h, 6h and 8h after dose administration. Bioanalytical analysis was perfomed using a validated HPLC-MS method which consisted on the quantification of propofol in rat whole-blood by high pressure liquid chromatography and fluorescence detection (excitation wavelength 270 nm, emission wavelength 314 nm). Thymol and 2, 4 -di-tert-butylphenol (DTBP) were used as internal standard.
Table 6. Overview of the prodrug formulations used.
Compound of Example Dissolved in Prodrug Cone Eq. Propofol Cone (mg/ml) (mg/mL)
1 PBS (pH=7.0) 7.15 3
2 PBS (pH=7.0) 8.13 3
4 a 10% Vitamin E TPGS 14.81 1.75
3 miglyol 812 9.51 2.44 a D-alpha-tocopheryl polyethylene glycol 1000 succinate solution
PK analysis
Non-compartmental PK analysis of the propofol plasma concentrations was performed using WinNonlin Phoenix 6.1 in order to estimate peak plasma concentration and systemic exposure of propofol after the administration of each propofol prodrug. Based on the individual propofol plasma concentration-time data, at least the following PK parameters of propofol were estimated in all rats receiving a dose of propofol prodrug:
Cmax peak plasma concentration, determined by visual inspection of the data tmax time to reach the peak plasma concentration, determined by visual inspection of the data
AUC last area under the plasma concentration-time curve from 0 to t hours post dosing, calculated by trapezoidal summation (time t is the time of the last quantifiable concentration Ciast).
AUCaIl area under the plasma concentration-time curve from 0 to t hours post dosing, calculated by trapezoidal summation (time t is the time of the last sampling point).
If the last concentration is non-zero AUCaii=AUCiast. Otherwise, AUCan will be greater than AUCiast as it includes the additional area from the last measurable concentration down to zero.
Auα AUCt extrapolated to infinity, calculated as AUCt + Ciast/λz λz elimination rate constant, determined by linear regression of the terminal points of the In- linear plasma concentration-time curve terminal half-life, defined as 0.693/λz
PK parameters were calculated for propofol after the administration of the propofol prodrugs pepared in Examples 1-4. The PK parameters ± SEM obtained with WinNonlin Phoenix 6.1 after the administration of the propofol prodrugs are summarized in Table 7. This table also includes the mean PK parameters ± SEM of propofol after iv and po administration of Diprivan®.
Table7. Mean PK parameters ± SEM of propofol after iv administration of Diprivan®, and oral administration of Di rivan®, and the ro ofol rodru s of Exam les 1-4
a Expressed in propofol equivalents b Corresponds to Co extrapolated from the data c Based on AUCo-2h d For prodrug of Example 1, the mean value of AUCiast is higher than the mean value of AUC∞.
Please note that the descriptive statistics on both parameters are based on different sample sizes because not all rats had both assessable AUCiast and AUC∞. For all rats that had assessable values for both parameters, the AUC∞ always exceeded the AUCiast
- Not estimable from the data
Claims
1. A compound represented by the structural formula (I):
- a single bond,
- each R3 and each R4 is independently selected from the group consisting of Ci_2oalkyl, C3-12alkyl, C3-i2cycloalkyl-Ci_4alkyl, saturated heterocyclyl and saturated heterocyclyl- Ci_4alkyl, and
- X and Y are each independently C or S(O), - Z is selected from the group consisting of O, S(O) and NR5,
- W is selected from the group consisting of halogen, OH, S(O)H and 0"M+ wherein M+ is a monovalent cation; and
- R5 is selected from the group consisting of hydrogen and C1-10 alkyl.
2. The compound according to claim 1, being represented by the structural formula (I), wherein a single bond,
- p is an integer from 2 to 3; - each R3 and each R4 is independently selected from the group consisting of Ci_2oalkyl and C3-i2alkyl;
- X and Y are each independently C;
- Z is O;
- W is selected from the group consisting of halogen and OH.
3. A compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof, for use as a medicament.
4. A compound according to any one of claims 1 to 2, for use as an anesthetic agent, sedative- hypnotic, or as anti-migraine agent.
5. A method of induction or maintenance of anesthesia, which comprises administering an effective amount of a compound according to any one of claims 1 to 2, to a patient in need of such induction or maintenance.
6. A method of extending the release of propofol, which method comprises converting propofol into a compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 2, and one or more pharmaceutically acceptable excipients.
8. The pharmaceutical composition according to claim 7, wherein said pharmaceutical compostion is administered orally.
9. The pharmaceutical composition according to claim 7, being in the form of an injectable.
10. A method for producing a compound according to claim 1 and being represented by the structural formula (I), wherein L is a single bond, said method comprising the steps of : - reacting propofol with a phosphorus oxyhalide to produce a phosphorus oxyhalide intermediate with the structural formula (II), wherein Q is a halogen; and
- (H)
- reacting the phosphorus oxyhalide intermediate (II) with a saturated acyclic, homocyclic or heterocyclic mono-alcohol R3OH wherein R3 is as defined in claim 1.
11. A method for producing a compound according to claim 1 and being represented by the structural formula (I), wherein L is -(CH2)P-O-X(O)-, X is C or S(O) and p is an integer from 1 to 8, said method comprising the steps of: - reacting a carbonyl chloride R3COCl or sulfonyl chloride R3SO2Cl, wherein R3 is as defined in claim 1, with a linear acyclic diol represented by the structural formula HO- (CH2)P-OH, to form an intermediate represented by the structural formula R3X(O)O- (CH2)p-OH;
- reacting propofol with a phosphorus oxyhalide to produce a phosphorus oxyhalide intermediate with the structural formula (II) as defined in claim 8; and
- reacting the intermediate R3X(O)O-(CH2)P-OH with the latter phosphorus oxyhalide intermediate (II) to form a compound of formula (I) according to claim 1, wherein W is a halogen.
12. The method according to claim 11, further comprising hydro lysing the compound of formula (I) wherein W is a halogen into the corresponding phosphonyl-containing propofol derivative (I) according to claim 1 , wherein W is hydro xyl.
13. The method according to any one of claims 10 to 12, wherein said acyclic diol is selected from the group consisting of ethylene glycol, 1,3-propanediol, 1,4-butanediol, 1,5- pentanediol, 2,4-dimethyl-2,4-pentanediol, 2,5-dimethyl-2,5-hexanediol, 1,6-hexanediol, and 1,8-octanediol.
14. The method according to any one of claims 10 to 13, wherein said carbonyl chloride R3COCl is selected from the group consisting of acetyl chloride, propionyl chloride, butyryl chloride, isobutyryl chloride, valeryl chloride, isovaleryl chloride, pivaloyl chloride, capryloyl chloride, nonanoyl chloride, decanoyl chloride, lauroyl chloride, myristoyl chloride, palmitoyl chloride, stearoyl chloride, cyclobutanecarbonyl chloride, cyclopentanecarbonyl chloride, cyclohexanecarbonyl chloride, 1 -methyl- 1- cyclohexanecarbonyl chloride, 2-methyl-l -cyclohexanecarbonyl chloride, 3-methyl-l- cyclohexane-carbonyl chloride, 4-methyl-l-cyclo-hexanecarbonyl chloride, cycloheptane- carbonyl chloride, 1-adamantanecarbonyl chloride, cyclohexylacetyl chloride, cyclopentylacetyl chloride, 2-norbornaneacetyl chloride, 1-adamantane-carbonyl chloride, 4- morpholinylcarbonyl chloride, 1-pyrrolidinecarbonyl chloride, tetrahydro-2-furancarbonyl chloride, 3-(l,3-dioxan-2-yl)-propionyl chloride, and 3-(l,3-dioxan-2-yl)-2-methylpropionyl chloride.
15. The method according to any one of claims 11 to 14, wherein said sulfonyl chloride R3SO2Cl is selected from the group consisting of methanesulfonyl chloride, ethanesulfonyl chloride, 1-propanesulfonyl chloride, 1-butanesulfonyl chloride, 1-hexanesulfonyl chloride,
1-octanesulfonyl chloride, 1-decane-sulfonyl chloride, cyclopentanesulfonyl chloride, cyclohexanesulfonyl chloride, 4-morpholinesulfonyl chloride, and pyrrolidine- 1 -sulfonyl chloride.
16. A method for producing a compound according to claim 1 and being represented by the structural formula (I), wherein L is -(CH2)P-O- and p is an integer from 1 to 8, said method comprising the steps of:
- reacting a saturated acyclic, homocyclic or heterocyclic mono-alcohol R3OH wherein R3 is as defined in claim 1, with an ω-halo α-alcohol represented by the structural formula Q-(CH2)P-OH wherein p is an integer from 1 to 8 and Q is a halogen, to form a substituted alcohol intermediate represented by the structural formula R 0-(CH2)p-0H; and
17. The method according to claim 16, further comprising hydro lysing the compound of formula (I) according to claim 1 wherein W is a halogen into the corresponding phosphonyl- containing propofol derivative (I) according to claim 1, wherein W is hydro xyl.
18. The method according to claim 16 or claim 17, wherein said ω-halo α-alcohol is selected from the group consisting of 2-bromoethanol, 3-bromopropan-l-ol, 4-bromobutan-l-ol, 5- bromopentan-1-ol, 6-bromohexan-l-ol, 7-bromoheptan-l-ol, 8-bromooctan-l-ol, and isomers thereof.
19. A method for producing a compound according to claim 1 and being represented by the
- R4, X, and Y are as defined in claim 1, said method comprising the steps of:
- reacting propan-l,2,3-triol with one or more carbonyl chlorides R4COCl and/or sulfonyl chlorides R4SO2Cl to form a l,3-di(acyloxy)-propan-2-ol and/or l,3-di(sulfoxy)-propan-2-ol intermediate;
20. A method according to claim 19, further comprising hydro lysing the compound of formula (I) according to claim 1 wherein W is a halogen into the corresponding phosphonyl- containing propofol derivative (I) according to claim 1, wherein W is hydro xyl.
21. A method according to any one of claims 12, 17 and 20, further comprising the step of converting the said phosphonyl-containing propofol derivative wherein W is hydroxyl into the corresponding salt wherein W is 0"M+ and M+ is a monovalent cation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0905834.8 | 2009-04-03 | ||
GBGB0905834.8A GB0905834D0 (en) | 2009-04-03 | 2009-04-03 | Phosphonyl-containing phenolic derivatives useful as medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010115869A1 true WO2010115869A1 (en) | 2010-10-14 |
Family
ID=40750084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/054502 WO2010115869A1 (en) | 2009-04-03 | 2010-04-06 | Propofol phosphonyl derivatives, synthesis, and use in long acting formulations |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0905834D0 (en) |
WO (1) | WO2010115869A1 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208224A (en) * | 1991-03-13 | 1993-05-04 | Warner-Lambert Company | Phosphorus containing compounds as antihypercholesterolemic and antiatherosclerotic agents |
WO1999058555A2 (en) | 1998-05-08 | 1999-11-18 | Vyrex Corporation | Water-soluble pro-drugs of 2,6-diisopropylphenol analogues |
WO2000008033A1 (en) | 1998-08-07 | 2000-02-17 | The University Of Kansas | Water soluble prodrugs of hindered alcohols or phenols |
WO2002013810A1 (en) | 2000-08-15 | 2002-02-21 | Vyrex Corporation | Water-soluble prodrugs of propofol for treatment of migraine |
WO2005023204A2 (en) | 2003-09-09 | 2005-03-17 | Xenoport, Inc. | Aromatic prodrugs of propofol, compositions and uses thereof |
CA2548216A1 (en) | 2003-12-17 | 2005-06-30 | Mgi Gp, Inc. | Methods of administering water-soluble prodrugs of propofol for extended sedation |
UA76802C2 (en) | 2001-12-28 | 2006-09-15 | Мгі Гп, Інк. | Aqueous based formulations of water-soluble prodrugs of propofol (variants) |
WO2007008869A1 (en) | 2005-07-12 | 2007-01-18 | Mgi Gp, Inc. | Methods of dosing propofol prodrugs for inducing mild to moderate levels of sedation |
-
2009
- 2009-04-03 GB GBGB0905834.8A patent/GB0905834D0/en not_active Ceased
-
2010
- 2010-04-06 WO PCT/EP2010/054502 patent/WO2010115869A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208224A (en) * | 1991-03-13 | 1993-05-04 | Warner-Lambert Company | Phosphorus containing compounds as antihypercholesterolemic and antiatherosclerotic agents |
WO1999058555A2 (en) | 1998-05-08 | 1999-11-18 | Vyrex Corporation | Water-soluble pro-drugs of 2,6-diisopropylphenol analogues |
WO2000008033A1 (en) | 1998-08-07 | 2000-02-17 | The University Of Kansas | Water soluble prodrugs of hindered alcohols or phenols |
US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
WO2002013810A1 (en) | 2000-08-15 | 2002-02-21 | Vyrex Corporation | Water-soluble prodrugs of propofol for treatment of migraine |
UA76802C2 (en) | 2001-12-28 | 2006-09-15 | Мгі Гп, Інк. | Aqueous based formulations of water-soluble prodrugs of propofol (variants) |
WO2005023204A2 (en) | 2003-09-09 | 2005-03-17 | Xenoport, Inc. | Aromatic prodrugs of propofol, compositions and uses thereof |
CA2548216A1 (en) | 2003-12-17 | 2005-06-30 | Mgi Gp, Inc. | Methods of administering water-soluble prodrugs of propofol for extended sedation |
WO2007008869A1 (en) | 2005-07-12 | 2007-01-18 | Mgi Gp, Inc. | Methods of dosing propofol prodrugs for inducing mild to moderate levels of sedation |
Non-Patent Citations (13)
Title |
---|
"Encyclopaedia of Surfactants", 1981, CHEMICAL PUBLISHING CO. |
"McCutcheon's Detergents and Emulsifiers Annual", 1981, MC PUBLISHING CROP. |
"Tensid-Taschenbuch", 1981, HANSER VERLAG |
BAKER ET AL., ANESTHESIOLOGY, vol. 103, 2005, pages 860 - 876 |
BANASZCZYK MARIUSZ G ET AL: "Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation", ANESTHESIA AND ANALGESIA, WILLIAMS AND WILKINS, BALTIMORE, MD, US LNKD- DOI:10.1097/00000539-200211000-00034, vol. 95, no. 5, 1 November 2002 (2002-11-01), pages 1285 - 1292, XP002519403, ISSN: 0003-2999 * |
DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 1998, LEE ET AL: "Phosphorochloridic acid 2,6-diisopropyl-phenyl ester methyl ester", XP002588353, Database accession no. 7878877 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1993, BOLTON, GARY L. ET AL: "Phosphorus containing compounds as antihypercholesterolemic and antiatherosclerotic agents", XP002588352, retrieved from STN Database accession no. 1993:495833 * |
GIBIANSKY ET AL., ANESTHESIOLOGY, vol. 103, 2005, pages 718 - 729 |
GONG-XIN HE ET AL: "Chapter 3.6. Prodrugs of Phosphonates, Phosphinates, and Phosphates", 1 January 2007, PRODRUGS CHALLENGES AND REWARDS PART 1 (BOOK SERIES: BIOTECHNOLOGY: PHARMACEUTICAL ASPECTS), SPRINGER NEW YORK, US LNKD- DOI:10.1007/978-0-387-49785-3_25, PAGE(S) 923 - 964, ISBN: 978-0-387-49782-2, XP001539680 * |
KUMPULAINEN ET AL., EUR J PHARM SCI., vol. 34, no. 2-3, 2008, pages 110 - 117 |
LEE ET AL, BIOORG. MED. CHEM. LETT., vol. 8, 1998, pages 289 - 294 * |
SCHYWALSKY ET AL., EUR JANAESTHESIOL, vol. 20, 2003, pages 182 - 190 |
STRUYS ET AL., ANESTHESIOLOGY, vol. 103, 2005, pages 730 - 743 |
Also Published As
Publication number | Publication date |
---|---|
GB0905834D0 (en) | 2009-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7767662B2 (en) | Analogs of benzoquinone-containing ansamycins and methods of use thereof | |
EP0966476B1 (en) | Quinazolinone compounds | |
JP2017128605A (en) | Solid forms of antiviral compound | |
US20060019941A1 (en) | Analogs of benzoquinone-containing ansamycins and methods of use thereof | |
PL198141B1 (en) | Water soluble prodrugs of hindered alcohols or phenols | |
JPH0859677A (en) | Alkylphosphocholin derivative and its production | |
US20140171394A1 (en) | Cyclitols and their derivatives and their therapeutic applications | |
US20220324841A1 (en) | Therapeutic compounds | |
US20080306028A1 (en) | Erianin Salts, Their Preparation Methods and Pharmaceutical Compositions Containing the Same | |
WO2010115869A1 (en) | Propofol phosphonyl derivatives, synthesis, and use in long acting formulations | |
CN114621135B (en) | LPA1 small molecule antagonist | |
KR900006132B1 (en) | Gem - dihalo - 1,8 -diamino - 4- aza - octane | |
US8097752B2 (en) | Antiprotozoal ring-substituted phospholipids | |
TW201625543A (en) | Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases | |
WO2006088080A1 (en) | CYCLOHEPTA[b]PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | |
WO2021138561A1 (en) | Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same | |
WO2010100186A1 (en) | Fluconazole carboxylic ester derivatives, synthesis, and use in long acting formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10714874 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10714874 Country of ref document: EP Kind code of ref document: A1 |